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ABSTRACT 
THREE ESSAYS ON ENHANCING  
CLINICAL TRIAL SUBJECT RECRUITMENT USING 
NATURAL LANGUAGE PROCESSING AND TEXT MINING 
 
By 
Euisung Jung 
 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Dr. Hemant Jain and Dr. Atish Sinha 
 
 Patient recruitment and enrollment are critical factors for a successful clinical 
trial; however, recruitment tends to be the most common problem in most clinical trials. 
The success of a clinical trial depends on efficiently recruiting suitable patients to 
conduct the trial. Every clinical trial research has a protocol, which describes what will be 
done in the study and how it will be conducted. Also, the protocol ensures the safety of 
the trial subjects and the integrity of the data collected. The eligibility criteria section of 
clinical trial protocols is important because it specifies the necessary conditions that 
participants have to satisfy. 
 Since clinical trial eligibility criteria are usually written in free text form, they are 
not computer interpretable. To automate the analysis of the eligibility criteria, it is 
therefore necessary to transform those criteria into a computer-interpretable format. 
Unstructured format of eligibility criteria additionally create search efficiency issues. 
Thus, searching and selecting appropriate clinical trials for a patient from relatively large 
number of available trials is a complex task. 
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 A few attempts have been made to automate the matching process between 
patients and clinical trials. However, those attempts have not fully integrated the entire 
matching process and have not exploited the state-of-the-art Natural Language Processing 
(NLP) techniques that may improve the matching performance. Given the importance of 
patient recruitment in clinical trial research, the objective of this research is to automate 
the matching process using NLP and text mining techniques and, thereby, improve the 
efficiency and effectiveness of the recruitment process.  
This dissertation research, which comprises three essays, investigates the issues of 
clinical trial subject recruitment using state-of-the-art NLP and text mining techniques.  
 
Essay 1: Building a Domain-Specific Lexicon for Clinical Trial Subject Eligibility 
Analysis 
Essay 2: Clustering Clinical Trials Using Semantic-Based Feature Expansion 
Essay 3: An Automatic Matching Process of Clinical Trial Subject Recruitment 
 
 In essay1, I develop a domain-specific lexicon for n-gram Named Entity 
Recognition (NER) in the breast cancer domain. The domain-specific dictionary is used 
for selection and reduction of n-gram features in clustering in eassy2. The domain-
specific dictionary was evaluated by comparing it with Systematized Nomenclature of 
Medicine--Clinical Terms (SNOMED CT). The results showed that it add significant 
number of new terms which is very useful in effective natural language processing In 
essay 2, I explore the clustering of similar clinical trials using the domain-specific lexicon 
and term expansion using synonym from the Unified Medical Language System (UMLS). 
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I generate word n-gram features and modify the features with the domain-specific 
dictionary matching process. In order to resolve semantic ambiguity, a semantic-based 
feature expansion technique using UMLS is applied. A hierarchical agglomerative 
clustering algorithm is used to generate clinical trial clusters. The focus is on 
summarization of clinical trial information in order to enhance trial search efficiency. 
Finally, in essay 3, I investigate an automatic matching process of clinical trial clusters 
and patient medical records. The patient records collected from a prior study were used to 
test our approach.  The patient records were pre-processed by tokenization and 
lemmatization. The pre-processed patient information were then further enhanced by 
matching with breast cancer custom dictionary described in essay 1 and semantic feature 
expansion using UMLS Metathesaurus. Finally, I matched the patient record with clinical 
trial clusters to select the best matched cluster(s) and then with trials within the clusters. 
The matching results were evaluated by internal expert as well as external medical expert. 
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CHAPTER 1 
INTRODUCTION 
 
"Never before in history has innovation offered  
promise of so much to so many in so short a time." 
Bill Gates 
 
 Basic science research has flourished over the past few decades and transferred 
knowledge into dramatic scientific advances for the treatment and prevention of human 
disease. As a result of these advances, new therapeutic agents, procedures, and devices 
have appeared. The healthcare industry has experienced decades of growth and success 
(Nussenblatt and Meinert, 2010). 
 Ever since the evidence-based practice was adopted, efforts have increased to 
base medical care as much as possible on the evidence of scientific research rather than 
on expert opinion or personal experience (National Research Council, 2001). A scientific 
experiment that provides one of the least biased type of clinical research evidence is the 
randomized controlled trial (RCT) (Sim et al., 2004). Moreover, RCTs are the most 
rigorous way to decide the existence of a cause-effect relationship between treatment and 
outcome (Sibbald and Ronalrd, 1998). In this sense, RCTs help to move basic scientific 
research from the laboratory into treatment for humans. 
 An RCT is also called a randomized clinical trial when it is applied to clinical 
research (Peto et al., 1976). A clinical trial is defined as “Research studies that explore 
whether a medical strategy, treatment, or device is safe and effective for humans” 
(National Institutes of Health, http://www.nhlbi.nih.gov/health/health-
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topics/topics/clinicaltrials/). The main objective of a clinical trial is to evaluate the 
efficacy and / or effectiveness of a medical intervention with human subjects. Thus, new 
treatment can be proven safe and effective before public deployment. Cautiously 
conducted clinical trials are considered the fastest and safest way to find new treatments 
(NLM, http://www.nlm.nih.gov/medlineplus/tutorials/clinicaltrials/).  
 It is clear that a clinical trial is one of most important resources of practical 
medical knowledge. Over the past decade, the total number of clinical studies registered 
on ClinicalTrials.gov, based on the First Received Date, has dramatically increased 
(Figure 1). ClinicalTrials.gov, run by the U.S. National Library of Medicine (NLM), is 
the official public registry of clinical trials. To date (as of July, 2015), there were more 
than 190,000 trials for about 5,000 diseases on ClinicalTrials.gov (ClinicalTrials.gov). 
  
Figure 1. Number of Registered Studies 
(ClinicalTrials.gov, 2015) 
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 Patient recruitment and enrollment are critical factors for successful clinical trial 
research (Fran, 2004), and it is well known that subject recruitment is the most common 
problem in most clinical trials (Ashery and Mcauliffe, 1992). Inadequate recruitment can 
disrupt a clinical trial research timetable, waste resources, reduce the trial’s ability to 
detect treatment effectiveness, and perhaps result in the failure of a clinical trial research 
project (Ashery and Mcauliffe, 1992). Accordingly, it is essential to achieve clinical trial 
research participant enrollment to conduct a successful trial (Frank, 2004). 
 In other words, the success of a clinical trial depends on efficiently recruiting 
suitable patients to conduct the trial. Insufficient patient participation from the time of a 
study’s initiation to closeout might incur lack of statistical power to prove or disprove the 
goal of the clinical trial research (Frank, 2004). The main cause of recruitment problems 
includes the need for large samples and multiple eligibility criteria, subject reluctance, 
low patient treatment motivation, client dislike of research procedures, clinicians’ distrust 
of research, and difficulties collaborating with treatment agencies. 
 Like other scientific research, every clinical research has a protocol that describes 
what will be done in the study and how it will be conducted. Also, the protocol ensures 
the safety of the trial subjects and integrity of the data collected. For this reason, it is a 
critical document for everyone involved in conducting the trial. In particular, the protocol 
of clinical trials should be followed precisely, since they deal with human subjects. In the 
U.S., diverse organizations, including the Office of Human Subjects Research Protection 
(OHRP) and the Food and Drug Administration (FDA), have the authority to determine 
whether certain clinical studies are adequately conducted according to their protocols. 
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 The eligibility criteria section of clinical trial protocols is important because it 
specifies the necessary conditions of clinical research participants (Luo et al., 2011). 
According to the definition from the U.S. National Library of Medicine (U.S. NLM, 
ClinicalTrials.gov), eligibility criteria for clinical trials are “the medical or social 
standards determining whether a person may or may not be allowed to enter a clinical 
trial; they are based on such factors as age, gender, the type and stage of a disease, 
previous treatment history, and other medical conditions.” 
 Since clinical research eligibility criteria are usually written in free text form, they 
are not computer interpretable. A popular method for achieving computable eligibility 
criteria is knowledge representation, which often requires labor-intensive manual effort 
and medical expert encoders in identifying the semantics of the eligibility criteria (Luo et 
al. 2010; Samson et al. 2011). No one can deny that standard-based formal computer 
understandable representation of eligibility criteria would provide obvious benefits for 
supporting clinical research and care use cases (Ross et al. 2010; Weng et al 2010). 
Therefore, the necessity for transforming free text eligibility criteria into a computable 
format has increased. In the last few years, a considerable number of attempts have been 
made at formal representations of eligibility criteria (Samson et al. 2011; Luo et al. 2010; 
Luo et al. 2010; Weng et al. 2010; Ross et al. 2010; Luo et al. 2013).  
 Unstructured characteristics of eligibility criteria raise other issues for search 
efficiency. It is not a simple task for a patient to search a huge repository and select 
appropriate clinical trials because subject eligibility criteria are not in a structured form 
but in free text form. The results from existing trial search engines usually are not 
satisfactory and require a manual process to refine relevant studies (Boland et al. 2013). 
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Boland et al. (2013) proposed feature-based indexing, clustering, and search of clinical 
trials, but their work still depends on a manual process by an expert for selection 
eligibility criteria features. To the best of my knowledge, no attempts have so far been 
made to build an entire automatic matching process for clinical trial clusters and patient 
information using state of art NLP and text mining algorithms. Given the importance of 
patient recruitment in clinical trial research, the objective of this dissertation is to build an 
integrated automatic matching process for clinical trials and patient information that 
enhances efficiency and effectiveness of the clinical trial subject recruitment process by 
using a NLP and Text Mining technique.  
 Essay 1 examines the building of a breast cancer domain-specific lexicon for n-
gram Named Entity Recognition (NER). The domain-specific dictionary is used for 
selection and reduction of word n-gram features in the clinical trial clustering and 
matching patients to clusters and clinical trials. Essay 2 explores clustering of similar 
clinical trials using the domain-specific lexicon built in Essay1 and a synonym 
relationship from the Unified Medical Language System (UMLS). I generated word n-
gram features and modified the features with the domain-specific dictionary matching 
process. In order to resolve semantic ambiguity, all synonym tags from the UMLS are 
annotated to the original features. A hierarchical agglomerative clustering (HAC) 
algorithm is used to generate clinical trial clusters. The focus of essay 2 is to examine the 
summarization of clinical trial information at cluster level to enhance trial search 
efficiency. Finally, essay 3 investigates an automatic matching process for patient 
information with clinical trial clusters and clinical trials within matched clusters. 
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Figure 2. Steps in Patient and Clinical Trial Matching  
Using a Domain Specific Dictionary and UMLS Synonyms 
 Figure 2 shows all the research steps included in essays 1, 2, and 3. 
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Essay 1: Building a Domain-Specific Lexicon for Clinical Trial Subject Eligibility 
Analysis 
 It is well understood that an NLP application requires sophisticated lexical 
resources to support its processing goals. Different solutions have been proposed to 
identify multi-gram disease named entities in the healthcare informatics literature. Jimeno 
et al. (2008) found that dictionary look-up provides competitive results with statistical 
approach and MetaMap solution, indicating that the use of disease terminology is highly 
standardized throughout the terminologies and the literature. Although there has been 
extensive effort made in the identification of protein- and gene-named entities (PGNs) in 
the biomedical literature, little research has been done on the recognition and resolution 
of terminologies in the clinical trial subject eligibility analysis. 
 A lexicon plays a significant role in all forms of medical language processing 
(Luo et al., 2010). At present, there is no comprehensive lexicon to capture multi-gram 
medical terminology in clinical trial eligibility criteria, especially in the breast cancer 
domain. 
 The goal of essay 1 is to build a breast cancer specific lexicon to cover clinical 
trial eligibility criteria and complete the multi-gram medical terminology. 
 
Essay 2: Clustering Clinical Trials Using Semantic-Based Feature Expansion 
 With so much data and information around us, it becomes a problem to find 
pieces that are relevant. Therefore, a great deal of effort has been made to reduce the 
clinical trial search space. However, most of the proposed solutions require users to 
understand data structure and to generate complex database queries. The need for 
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understanding various medical terminologies remains an unsettled issue. The Unified 
Medical Language System® (UMLS®) was initiated and is now being maintained by 
The National Library of Medicine (NLM). The objective of UMLS is to facilitate the 
development of computer systems that deal with the semantics of the language of 
biomedicine and healthcare. In essay 2, I propose a novel clustering method to narrow the 
clinical trial search space using a custom dictionary and the UMLS Semantic Network. 
 
Essay 3: An Automatic Matching Process for Clinical Trial Subject Recruitment 
 The process of new treatment and new drug development is extremely time 
consuming and expensive. A key bottleneck in this process is subject recruitment in 
clinical trials. Of all clinical trials conducted globally, more than 80% are delayed due to 
slow patient recruitment. This delay may cost the pharmaceutical companies millions of 
dollars per day in terms of lost sales. Speeding up patient recruitment in clinical trials can 
result in lower drug development costs and, ultimately, new drugs that are more 
affordable to patients. 
 In essay 3, I propose a novel automatic matching process of clinical trials and 
patient medical records. First, patient records were collected from a prior study and were 
pre-processed for tokenization and lemmatization. Second, the pre-processed patient 
records were matched with breast cancer custom dictionary and UMLS Metathesaurus for 
semantic feature expansion. Finally, I compared each pre-processed patient record with 
clinical trial clusters and each clinical trial study within matched clusters. The matching 
results are evaluated by internal expert as well as external medical expert.   
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CHAPTER 2 
Essay 1: Building a Domain-Specific Lexicon for  
Clinical Trial Subject Eligibility Analysis 
 
“Not everything that can be counted counts  
and not everything that counts can be counted” 
Albert Einstein 
 
2.1. Introduction 
 There is a growing number of healthcare-related corpora and document data in the 
free text form, and with this comes the need to analyze and draw meaningful information. 
However, it is not easy to retrieve and query relevant information from text data. There 
have been several attempts at applying NLP and text mining techniques to the healthcare 
domain.  
 Clinical trials are designed to answer specific questions about the effects of a 
therapy or technique designed to improve human health. They rely on eligibility criteria, 
which specify who is qualified for clinical research study participation and who is 
disqualified. However, analysis of clinical trial subject eligibility text is not a typical text 
analysis task since it has some intriguing characteristics. In particular, the clinical trial 
subject eligibility section comprises a variety of biomedical terms that include 
abbreviations and acronyms. Moreover, clinical trial subject eligibility texts are not 
usually complete syntactically. They are not depicted by complete sentences, but outlined 
by succinct and fragmented phrases. For example, a sentence in the inclusion criteria of 
the clinical trial id ‘NCT01068483’ is ‘Progressive, recurrent unresectable disease’ which 
is not a grammatically complete sentence. 
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 There is an increasing need to efficiently transform these free text clinical 
research eligibility criteria into computable formats to support the subject recruitment 
process. Various approaches have been proposed to achieve high-performance text 
analysis of clinical trial subject eligibility criteria. Prior work has typically used the Bag 
of Words (BOW) model as features for text analysis. However, the BOW approach does 
not recognize multi-word terms, which are typical in medical and healthcare domains.
 The term dependency is the issue in the general BOW approach. The n-gram 
model takes into consideration the context information of a word, which depends on a 
previous or next word (Khan, 2010). But while the n-gram model improves the text 
analysis performance, it decreases the performance if the word length of n is greater than 
3 (Liu, 2008). 
 A lexicon is fundamental to all forms of medical language processing and plays a 
significant role (Lou et al. 2010). Dictionary-based n-gram features induction, in which 
only those n-grams that appear in a pre-defined dictionary are used as features (Remus 
and Rill, 2013). The n-gram feature induction approach yields the most accurate 
discriminative model for machine learning-based text analysis within a specific domain. 
Moreover, the dictionary-based n-gram feature induction leads to large dimensionality 
reductions. Thus, this feature selection may significantly reduce both noise and feature 
space size. 
 At present, there is no lexicon resource for identifying the n-gram terms in breast 
cancer clinical trial eligibility. In this essay, I build a domain-specific lexicon to facilitate 
analysis of a breast cancer clinical trial subject eligibility section. To the best of my 
knowledge, such a study has not been carried out before.  
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This essay is structured as follows. The next section reviews prior research in 
lexicon-building. In section 2.3, I describe short representations of textual documents, 
term frequency, inverse document frequency, data-driven n-gram feature induction, and 
the dictionary-based word n-gram feature induction approach. In section 2.4, the n-gram 
lexicon building process is described, and I compare the proposed lexicon and UMLS to 
evaluate its effectiveness in section 2.5. Finally, I draw conclusions and point out 
possible directions for future work in section 2.6. 
 
2.2. Background Literature 
 Over the past few years, there have been several studies on clinical trials that use 
the text mining approach. One of the salient research streams is formal representation of 
eligibility criteria (Weng et al. 2009). Tu et al (2011) examined formalizing eligibility 
criteria in a computer-interpretable language to facilitate eligibility determination for 
study subjects and the identification of studies on similar patient populations. ERGO 
(Eligibility Rule Grammar and Ontology) annotation is used for capturing the semantics 
of criteria. Luo et al. (2013) examined a semi-automatic process to extract Common Data 
Elements (CDEs) in eligibility criteria of clinical trials. Luo et al. (2013)’s study is the 
first study using text mining in CDE discovery from free text clinical trial eligibility 
criteria. 
 There have been foundational studies on enhancing eligibility criteria 
representation. Luo et al. (2010) presented a corpus-based approach to create a semantic 
lexicon for clinical research eligibility criteria using UMLS.  The main purpose of that 
research was to reduce the ambiguity in UMLS sematic-type assignment while building a 
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semantic lexicon for clinical trial eligibility criteria. A total of 20 UMLS semantic types, 
representing about 17% of all the distinct semantic types assigned to corpus lexemes, 
covered about 80% of the vocabulary of our corpus. 
 Temporal knowledge representation from temporal express in clinical research 
eligibility criteria is also a topic being actively investigated. Boland et al (2012) identified 
the temporal knowledge representation requirements of eligibility criteria by reviewing 
annotated 100 eligibility criteria. They developed EliXR-TIME, a frame-based 
representation designed to support semantic annotation for temporal expressions in 
eligibility criteria by reusing applicable classes from well-known clinical temporal 
knowledge representations (Boland et al, 2012). Luo et al. (2011) presented an ontology-
based approach for extracting temporal information from clinical trial eligibility criteria. 
They developed a Conditional Random Field (CRF)-based parser, which is based on 
Temporal Awareness and Reasoning Systems for Question Interpretation (TARSQI) 
toolkit and the TimeText project, to automatically annotate the elements of temporal 
constraints, specifically focusing on clinical trial eligibility criteria. The results were 
evaluated with an additional 60 randomly selected eligibility criteria. 
 Another active research topic is effective and efficient search of  clinical trials. 
Korkontzelos et al (2012) presented Assisting Search and Creation Of clinical Trials 
(ASCOT), a search application focused on clinical trials. Text mining and data mining 
methods were applied to ASCOT and an eligibility criteria recommendation component 
was included.  
 There has been much research on application, usage, and evaluation of UMLS. 
Wu et al. (2012) examined characteristics of UMLS Metathesaurus terms in clinical 
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notes. A 51 million document corpus of Mayo Clinic clinical notes was analyzed with 
modified Aho-Corasick algorithm and the occurrences of UMLS terms were statistically 
computed in terms of string attributes, source terminologies, semantic types, and 
syntactic categories. They found that on average 44.64 term matched per document and 
only 3.56% of the available case-insensitive terms in the UMLS were utilized. Aronson et 
al. (2001) depicted a MetaMap program developed by the NLM to map biomedical text 
to the UMLS Metathesaurus or to discover Metathesaurus concepts referred to in text. 
Fung et al. (2010) investigated the problem list terminologies (PLT) of large healthcare 
institutions and identified a subset of concepts based on standard terminologies. Data 
were acquired from six large-scale healthcare institutions and mapped with the UMLS 
Metathesaurus.  
 Feature selection and summarization of clinical trial is an emerging research 
topic. Boland et al. (2013) investigated the feasibility of feature-based indexing, 
clustering, and search of clinical trials. They argued that concept-oriented eligibility 
features could enhance user search effectiveness, facilitating meaningful and efficient 
indexing for clinical trials. In their study, concept-oriented eligibility features are a 
clinically meaningful atomic patient state, such as diagnosis, symptom, or demographic 
characteristics, which are derived from eligibility criteria. They argued that no studies 
have ever examined feature-based indexing for clinical trials system; thus, their work 
could set a baseline.  
 The ultimate goal of eligibility criteria analysis is directed at the automatic 
matching process between a clinical trial and patients. Wilcox et al. (2009) presented a 
model, electronic Participant Identification and Recruitment Model (ePaIRing), which 
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uses patient information to enhance patient recruitment in clinical trials. The model was 
created by grounded theory analysis, which is a qualitative approach. It iteratively collect 
and interpret data to arrive at explanation of data (Wilcox et al., 2009). 
 Over the past decades a considerable number of studies have been done on 
clinical trial and its subject eligibility criteria. However, no studies have ever tried to 
generate a domain-specific lexicon resource, even though it is recognized that a domain-
specific lexicon is fundamental of medical text analysis and foundation of NLP and text 
mining. Thus, in the first essay, I generated a breast cancer-specific multi-gram lexicon 
by inducing high impacted multi-gram terms from clinical trial description as well as 
integrating heterogeneous online resources. 
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 Table 1 show the selected research on clinical trial 
Table 1. Selected Research on Clinical Trial 
Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Boland MR, 
Miotto R, Gao J, 
Weng C, 
Methods of 
Information in 
Medicine (2013) 
Feasibility of Feature-based 
Indexing, Clustering, and 
Search of Clinical Trials on 
ClinicalTrials.gov: A Case 
Study of Breast Cancer Trials, 
    
Luo Z, Miotto R, 
Weng C, 
Journal of 
Biomedical 
Informatics 
(2012) 
A Human-Computer 
Collaborative Approach to 
Identifying Common Data 
Elements in Clinical Trial 
Eligibility Criteria 
To identify 
Common Data 
Elements (CDEs) in 
eligibility criteria 
association rule-
learning algorithm , 
UMLS, dice 
coefficient 
Clinicaltrials.o
rg (breast 
cancer and 
cardiovascular
) 
 
Weng C, Wu X, 
Luo Z, Boland M, 
Theodoratos D, 
Johnson SB 
Journal of the 
American 
Medical 
Informatics 
Association, 
(2011) 
EliXR: An Approach to 
Eligibility Criteria Extraction 
and Representation 
    
Luo Z, Yetisgen-
Yildiz M, Weng C, 
Journal of 
Biomedical 
Informatics, 
(2011) 
Dynamic Categorization of 
Clinical Research Eligibility 
Criteria by Hierarchical 
Clustering 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Weng C, Tu SW, 
Sim I, Richesson 
R 
Journal of 
Biomedical 
Informatics 
(2010) 
Formal Representations of 
Eligibility Criteria: A 
Literature Review 
Review eligibility 
criteria knowledge 
representation 
Analyze 
publications 
PubMed, 
Google, 27 
systems 
 
Thadani S, Weng 
C, Bigger JT, 
Ennever J, 
Wajngurt D 
Journal of the 
American 
Medical 
Informatics 
Association 
(2009) 
Electronic Screening 
Improves Efficiency of 
Clinical Trials Recruitment 
evaluate the 
performance of an 
electronic screening 
(E-screening) 
method 
 
125 patients, 
investigator 
review 
significantly 
reduced the 
screening burden 
associated with the 
ACCORD trial 
Weng C, 
McDonald DW, 
Gennari JH, 
International 
Journal of 
Medical 
Informatics 
(2007) 
Participatory Design of a 
Collaborative Clinical Trial 
Protocol Writing System 
    
       
Mary Regina 
Boland, Samson 
W. Tu, Simona 
Carini, Ida Sim, 
Chunhua Weng 
Proc of 2012 
AMIA Clinical 
Research 
Informatics 
Summit 
ELIXR-TIME: A Temporal 
Knowledge Representation 
for Clinical Research 
Eligibility Criteria 
temporal 
expressions is 
needed to facilitate 
temporal 
information 
extraction 
 
100 eligibility 
criteria from 
ClinicalTrials.
gov 
EliXR-TIME, a 
frame-based 
representation 
designed to support 
semantic annotation 
for temporal 
expressions in 
eligibility criteria 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Luo Z, SB 
Johnson, AM Lai, 
Weng C 
Proc of 2011 
AMIA Fall 
Symposium 
Extracting Temporal 
Constraints from Clinical 
Research Eligibility Criteria 
Using Conditional Random 
Fields 
develop automated 
approaches for 
extracting the 
primary constructs 
of temporal 
constraints in 
clinical research 
eligibility criteria 
Conditional 
Random Fields 
(CRFs) to train a 
temporal parser 
from manually-
annotated criteria 
150 temporal 
eligibility 
criteria 
randomly 
selected from 
ClinicalTrails.
gov 
 
Weng C, Batres C, 
Borda T, Weiskopf 
NG, Wilcox AB, 
Bigger JT, 
Davidson K, 
Proc of 2011 
AMIA Fall 
Symposium 
A Real-Time Screening Alert 
Improves Clinical Trial 
Recruitment Efficiency 
    
Weng C, Bigger 
JT, Busacca L, A 
Wilcox, A 
Getaneh, 
Proc of AMIA 
2010 Fall 
Symposium 
Comparing the Effectiveness 
of a Clinical Data Warehouse 
and a Clinical Registry for 
Supporting Clinical Trial 
Recruitment: A Case Study 
    
Luo Z, Johnson 
SB, Weng C, 
Proc of AMIA 
2010 Fall 
Symposium 
Semi-Automatic Induction of 
Semantic Classes from Free-
Text Clinical Research 
Eligibility Criteria Using 
UMLS 
    
Luo Z, Duffy R, 
Johnson SB, Weng 
C 
Proc of AMIA 
Clinical Research 
Informatics 
Summit 2010 
Corpus-based approach to 
create a semantic lexicon for 
clinical research eligibility 
criteria using UMLS 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Wilcox AB, 
Natarajan K, 
Weng C 
Proc of AMIA 
Translational 
Bioinformatics 
Summit 2009 
Using Personal Health 
Records for Automated 
Clinical Trials Recruitment: 
the ePaIRing Model 
    
Li, L, Chase H, 
Patel C, Friedman 
C, and Weng C 
Proc of 2008 
AMIA Fall 
Symposium 
Comparing ICD9-Encoded 
Diagnoses and NLP-
Processed Discharge 
Summaries for Clinical Trials 
Pre-Screening: A Case Study. 
    
Weng C, Becich 
M, Fridsma D 
The 2nd 
International 
Conference on 
Information 
Technology and 
Communications 
in Health, Feb 
2007, 
Collective Domain Modeling 
across Clinical Trials 
Standards: Needs, 
Challenges, and Design 
Implications 
    
Weng C, Gennari 
JH, McDonald 
DW 
11th World 
Congress on 
Medical 
Informatics 
(MedInfo’04) 
A Collaborative Clinical Trial 
Protocol Writing System 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Gennari JH, Weng 
C, McDonald 
DW, Benedetti J, 
Green S 
11th World 
Congress on 
Medical 
Informatics 
(MedInfo’04) 
An Ethnographic Study of 
Collaborative Clinical Trial 
Protocol Writing 
    
Weng C, 
McDonald DW, 
Gennari JH 
IT in Health Care: 
Socio-technical 
Approaches 2nd 
International 
Conference, 13-
14 September 
2004 
Participatory Design of A 
Collaborative Clinical Trial 
Protocol Writing System 
    
Weng C, Kahn 
MG, Gennari JH 
Proc of AMIA 
2002 Fall 
Symposium 
Temporal Knowledge 
Representation for 
Scheduling Tasks in Clinical 
Trial Protocols. 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data Finding / Implication 
D.W. Lonsdale, 
C. Tustison, C.G. 
Parker, D.W. 
Embley 
Data & Knowledge 
Engineering (2008) 
Assessing clinical trial 
eligibility with logic 
expression queries 
identification, extraction, 
and query formulation of 
information 
regarding medical clinical 
trials 
web-based 
information 
extraction 
 Query generation 
Marc Cuggia, 
Paolo Besana, 
David Glasspool 
International journal 
of medical 
informatics (2011) 
Comparing semi-automatic 
systems for recruitment of 
patients to clinical trials 
review decision support 
systems for automatic 
recruitment of patients to 
clinical trials 
   
Ida Sim, Ben 
Olasov, and 
Simona Carini 
Journal of 
Biomedical 
Informatics (2004) 
An ontology of 
randomized controlled 
trials for evidence-based 
practice: content 
specification and 
evaluation using the 
competency decomposition 
method 
developing RCT Bank to 
capture detailed 
information 
about the design, 
execution, and results of 
RCTs 
 
competency 
decomposition 
 
RCT Schema using 
UMLS 
Y. Megan Kong, 
Carl Dahlke, Qun 
Xiang, Yu Qian, 
David Karp, 
Richard H. 
Scheuermann 
Journal of 
Biomedical 
Informatics(2011) 
Toward an ontology-based 
framework for clinical 
research databases 
integrate data 
standards and ontology 
structures of knowledge 
representation 
database 
implementation of 
the OBX model 
 
Ontology-Based 
eXtensible (OBX) data 
model 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data Finding / Implication 
Guoqian Jiang, 
Harold R. 
Solbrig, 
Christopher G. 
Chute 
Journal of 
Biomedical 
Informatics(2011) 
Quality evaluation of 
cancer study Common 
Data Elements using the 
UMLS Semantic Network 
relationship between 
terminological 
annotations and the 
UMLS Semantic 
Network (SN) that can be 
exploited to improve 
those annotations 
UMLS SN 
caDSR CDE 
Browser 
the UMLS SN based 
profiling approach is 
feasible 
for the quality 
assurance and 
accessibility of the 
cancer study 
CDEs 
P.J. Embi et al. 
Arch Intern Med, 
(2005) 
Effect of a clinical trial 
alert system on physician 
participation in trial 
recruitment 
    
P.A. Harris et al. Acad Med (2012) 
ResearchMatch: a national 
registry to recruit 
volunteers for clinical 
research 
    
S.W. Tu et al. 
Journal of 
Biomedical 
Informatics (2011) 
A practical method for 
transforming free-text 
eligibility criteria into 
computable criteria 
creating computer-
interpretable languages 
for eligibility criteria 
ERGO 
annotations 
1000 
eligibility 
criteria 
randomly 
drawn from 
ClinicalTrials
.gov 
incrementally 
capturing the 
semantics of free-text 
eligibility criteria 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data Finding / Implication 
J. Nahar et al. J Med Syst, 
Significant cancer 
prevention factor 
extraction: an association 
rule discovery approach 
    
Peter J. Embi, 
MD, MS; Anil 
Jain, MD; Jeffrey 
Clark, BS; Susan 
Bizjack, MSN; 
Richard 
Hornung, DrPH; 
C. Martin Harris, 
MD, MBA 
Arch Intern Med. 
(2005) 
Effect of a Clinical Trial 
Alert System on Physician 
Participation in Trial 
Recruitment 
the resources of a 
comprehensive EHR can 
be leveraged for the 
benefit of clinical trial 
recruitment 
EHR-based 
clinical trial alert 
(CTA) system 
From 
Cleveland 
Clinic 
The CTA intervention 
was associated with 
significant increases in 
the number of 
physicians 
Stephanie 
Heinemann, 
Sabine Thüring, 
Sven Wedeken, 
Tobias Schäfer, 
Christa Scheidt-
Nave, Mirko 
Ketterer, 
Wolfgang 
Himmel1 
BMC Medical 
Research 
Methodology 2011, 
A clinical trial alert tool to 
recruit large patient 
samples and assess 
selection bias in general 
practice research 
evaluate the recruitment 
performance of the 
practice staff when using 
the CTA tool according to 
4 criteria 
clinical trial alert 
(CTA) tool 
GP’s data  
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2.3. Background 
Tokenization 
 Tokenization is the process of breaking up a stream of text into words, 
phrases, symbols, or other meaningful elements called tokens. The list of tokens 
becomes input for further processing, such as parsing or text mining (Manning et al., 
2008). Manning et al. (2008) defined a token as “an instance of a sequence of 
characters in some particular document that are grouped together as a useful semantic 
unit for processing.” Table 2 explains an example of tokenization. 
 
Table 2. Example of Tokenization (Manning et al., 2008) 
Input Friends, Romans, Countrymen, lend me your ears 
Output Friends Romans Countrymen lend me your ears 
 
Lemmatization 
 For grammatical reasons, there are diverse forms of a word, such as organize, 
organizes, and organizing. Likewise, families of derivationally related words with 
similar meanings, such as democracy, democratic, and democratization, are common 
in textual data. In NLP and text mining, it is useful for a search of words to return 
documents that contain another word in the set. The goal of lemmatization is to 
reduce inflectional forms and derivationally related forms of a word to a common 
base form. 
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 There are two different approaches to obtain a common base form: stemming 
and lemmatization. Stemming refers to a crude process that cuts off the end of words 
in order to acquire a base form and includes the removal of derivational affixes. 
Lemmatization refers to a process that uses a vocabulary and morphological analysis 
of words for the purpose of removing inflectional endings and returning the base or 
dictionary form of a word called lemma. Lemmatization makes use of full 
morphological analysis to accurately identify the lemma for each word. In this study, 
I use lemmatization rather than stemming, which does not guarantee returning 
grammatically correct words. 
 Table 3 shows an example of lemmatization, and Table 4 shows an example 
of lemmatization with a sentence. 
 
Table 3. Example of Lemmatization (Manning et al., 2008) 
Base Form Inflectional or Derivationally related form 
be am, are, is 
car car, cars, car’s cars’ 
 
Table 4. Example of Lemmatization with a Sentence (Manning et al., 2008) 
Original Sentence the boy's cars are different colors 
Lemmatization the boy car be differ color 
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Stop Word Removal 
 A document is a combination of sentences, and a sentence is a set of words. A 
word is a complicated combination of characters. There is a variety of words and 
special characters that do not have significant meaning. Some extremely common 
words called stop words would appear to be of little value in NLP and text mining 
process.  Examples of stop words are “the,” “of,” “to,” and “a. ”  These are required 
to satisfy English grammar rules even though they  have no semantic meaning. 
Moreover, special characters such as the period and question mark used to indicate 
the end of a sentence or an interrogative sentence, respectively, are considered to be 
noise in NLP. Therefore, all of the stop words need to be removed in the pre-
processing step. 
 The general strategy for removing stop words in English is to use a stop list 
that is a negative dictionary. Fox (1989) reported a stop list based on the Brown 
corpus of 1,014,000 words drawn from a broad range of literature in English. The 
final product of Fox’s work is a list of 421 stop words that would be maximally 
efficient and effective in filtering the most frequently occurring and semantically 
neutral words.  
 This study adopts Fox’s stop list to cull all insignificant words in data. 
 
Representation of Textual Documents and Vector Space Model 
 Text representation is one of the pre-processing processes that is used to 
reduce the complexity of documents and make them easier to handle. To implement 
any technique of text mining, it is initially necessary to transform the digitized texts 
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in an efficient and meaningful way so that they can be analyzed. 
 The space vector model is the most commonly used approach to represent 
textual documents.  This approach represents a text by a numerical vector obtained by 
counting the most relevant lexical elements present in the text (Amine et al., 2008). 
 All documents d will be transformed into a vector: 
dj = (w1j ,w2j , ...,w|T|j)   (1) 
 
 Where T is the whole set of terms (or descriptors) that appear at least once in 
the corpus (|T| is the size of the vocabulary), and  represents the weight 
(frequency or importance) of the term tk in the document   
 Table 5 represents a Document Term Matrix model. 
Table 5. Document Term Matrix 
Documents Terms or Descriptors 
d1 w11 w21 w31 … wj1 … wn1 
d1 w12 w22 w32 … wj2 … wn2 
… … … … … … … … 
dm w1m w2m w3m … wjm … wnm 
 
 I represented each clinical trial document by a vector in a multidimensional 
space. Each word constitutes a dimension in this space. When a word is absent in a 
27 
 
 
clinical trial document, its value along the corresponding dimension is 0. When a 
word occurs in the document, the value along the dimension is determined by a 
weight factor indicating its importance. 
 The simplest representation of texts introduced within the framework of the 
vector space model is called Bag of Words (BOW) (Salton and McGil, 1986). It 
consists of texts transformed into vectors where each component represents a word. 
This representation of texts excludes any grammatical analysis and any concept of 
distance between the words, and syntactically destructures texts by making them 
understandable to the machine.  
 
Term Frequency - Inverse Document Frequency (TF-IDF) 
 TF-IDF is a numerical statistic that is intended to reflect how important a 
word is to a document in a collection or corpus. There are many methods to calculate 
the weight wkj knowing that for each term, it is possible to calculate not only its 
frequency in the corpus but also the number of documents that contain this term. 
 Most approaches (Sebastiani, 2002) are centered on a vectorial representation 
of texts using the TF-IDF measure. The frequency TF of a term T in a corpus of 
textual documents corresponds to the number of occurrences of the term T in the 
corpus. The frequency IDF of a term T in a corpus of textual documents corresponds 
to the number of documents containing T. These two concepts are combined (by 
product) in order to assign a stronger weight to terms that appear often in a document 
and rarely in the complete corpus. 
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TF×IDF, 
=Occ, 
× __() 
 Where Occ, 
 is the number of occurrences of the term   in the 
document , Nb_doc is the total number of documents of the corpus and Nb_doc() 
is the number of documents of this unit in which the term   appears at least once 
(Amine et al., 2008). 
 
N-gram and N-gram Induction 
 N-gram (Damashek, 1995) is a character sequence of length n extracted from 
a document. To generate the n-gram vector for a document, a window n characters in 
length is moved through the text, sliding forward by a fixed number of characters 
(usually one) at a time. At each position of the window, the sequence of characters in 
the window is recorded. For example, the first three 5-grams in the phrase “character 
string” are “chara,” “harac,” and “aract.”  Damashek (Damashek, 1995) suggested the 
use of character n-grams instead of words for gauging text similarity. N-gram 
retrieval promises lower vulnerability to data entry errors, spelling varieties, word 
conjugations, and other morphological varieties. 
 The concept of n-grams was first discussed in 1951 by Shannon (Shannon, 
1951). Since then, n-grams have been used in many areas, such as spelling-related 
applications, string searching, prediction and speech recognition.  Word n-gram is a 
sequence of consecutive tokens, with the length of n. Mostly words are taken as 
tokens, but in recent works, characters could also be token (Trenkle and Cavnar, 
1994).  
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 A word n-gram feature induction, sometimes also referred to as feature 
extraction, induces features on textual data based on a set of word n-grams. With 
feature induction, the textual data is represented in a feature space, usually encoding 
the existence of these word n-grams or their frequency. The word n-grams to be used 
as features may be chosen by either using a data driven approach or dictionary-based 
approach. 
 In a data driven feature induction, every word n-gram combination from the 
textual data is created. Thus, the feature size equals the word n-gram vocabulary size. 
Such a data driven feature induction does not require prior domain knowledge to 
recognize meaningful word n-grams.  
 In a dictionary approach, n-gram tokens are selected based on a custom 
lexicon database that focuses on a specific domain. In this approach, it is proposed 
that an n-gram feature selection that maps all bigram and trigram tokens to the custom 
lexicon database be used. 
 
Named Entity Recognition (NER) 
 Named Entity Recognition (NER) is the task of identifying and classifying 
entities such as person names, place names, organization names, etc., in a given 
document. Named entities play a major role in information extraction. A well-
performing NER is important for further levels of NLP techniques. Many techniques 
have been applied in English for NER. Some of them are rule-based systems (Krupka 
and Hausman, 1998), which make use of dictionary and patterns of named entities.  
Examples are Decision trees (Karkaletsis et al., 2000), Hidden Morkov Model 
(HMM) (Biker, 1997), Maximum Entropy Morkov Model (MEMM) (Borthwick et 
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al., 1998), and Conditional Random Fields (CRF) (Andrew McCallum and Wei Li, 
2003). The approaches can be classified as a rule-based approach, machine learning 
approach, or hybrid approach. 
 NER has been done generically but can also be domain-specific where a finer 
tagset is needed to describe the named entities in a domain. Domain-specific NER is 
common and has been in existence for a long time in the bio-domain (Settles 2004) 
for identification of protein names, gene names, DNA names, etc. The NER task is 
also viewed as the first step of information extraction of free text clinical studies 
describing shock, trauma, inflammation, and other related states (Apostolova et al., 
2008). The proposed custom dictionary also supports the NER process in the 
healthcare domain. 
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2.4. Research Method 
 
Figure 3. Steps for Building Domain Specific Dictionary 
 Figure 3 represents the steps for building breast cancer domain-specific 
dictionary in essay 1. 
  
32 
 
 
2.4.1 Data Set 
 I collected 378 clinical trials using search term ‘Breast Cancer’ that was listed 
in ClinicalTrials.gov between January 1, 2010 and January 1, 2011, and downloaded 
all the related information as a collection of individual XML files. 
 All XML tags and metadata were removed and only the <eligibility> - 
<criteria> - <textblock> section was extracted. Since subject eligibility criteria text is 
in free text format and contains two opposite criteria, “inclusion” and “exclusion”, I 
separated subject eligibility criteria text blocks based on the key words “Inclusion 
criteria” and “Exclusion criteria.” 
 
2.4.2 Building Dictionary 
 I constructed a domain-specific n-gram term dictionary for the breast cancer 
domain. The custom dictionary was based on high TF-IDF score words from the 
clinical trial eligibility data set and other online resources (i.e., NCI Dictionary of 
Cancer Terms, Breastcancer.org, and ACS Breast Cancer Dictionary). The n-gram 
term dictionary for breast cancer domain can be a resource for dictionary-based feature 
induction that uses a pre-defined dictionary as well as an NER process.  
 First, during pre-processing, tokenization, lemmatization, and stop word 
removal were performed over the selected data set. 
 Second, I calculated the TF-IDF score for all unigram features that drew from 
the breast cancer clinical trial eligibility text data set. Three experts reviewed all 
26,193 unigram list organized in descending order by TF-ID score, and they manually 
identified bigram and trigram terms from the unigram list. The review was conducted 
sequentially. The output of first reviewer was forwarded to second reviewer and the 
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results from second reviewer was validated by the third reviewer. The review process 
was iterated among three reviewers until all reviewer agreed on identified bigram and 
trigram. The final review was conducted by expert who is medical doctor as well as 
Ph.D. Only adjacent words were considered. After expert review, a total of 1,506 
multi-gram terms were identified. 
 Third, an online medical term crawler was developed by the author in Ruby 
language to gather breast cancer terms from web sites. The crawler automatically 
collected web documents from the targeted site and parsed the documents to extract 
medical terms. All unnecessary tags were removed. The crawler collected 4,704 terms 
from the NCI dictionary of Cancer Terms, 910 terms from Breastcancer.org, 155 
terms from the ACS Breast Cancer Dictionary, and 28 terms from breast cancer 
glossary of Terms in emedicinehealth.com. All the collected items were stored in 
MySql database and duplicates were removed by SQL query. Table 6 shows the 
number of dictionary items by the source. 
 
Table 6. Number of Item by Source 
Source Number of item 
NCI Dictionary of Cancer Terms 4,704 
Clinical Trial cluster 1,506 
Breastcancer.org 910 
ACS Breast Cancer Dictionary 155 
emedicinehealth.com 28 
Total 7,303 
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 The custom dictionary included total 7,303 items. The dictionary included 707 
trigram, 2,098 bigram, 4,162 unigram, and 336 n-grams terms consisting of more than 
three words that were identified. Table 7 shows the number of dictionary items by the 
type of n-gram. 
 
Table 7. Number of Item by N-Gram Type 
Type of n-gram Number of item 
1 4,162 
2 2,098 
3 707 
4 191 
5 93 
6 37 
7 11 
8 3 
9 1 
Total 7,303 
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2.5. Evaluation 
 Two experiments were conducted to evaluate the efficiency of the domain-
specific dictionary. First, all items in the custom dictionary were directly matched 
with the SNOMED CT in UMLS Metathesaurus to examine uniqueness of the custom 
dictionary items. Only English terms in SNOMED CT were used for evaluation. I 
created a database query with Structured Query Language (SQL) and ran the query to 
evaluate uniqueness. The SQL query selected all items in the custom dictionary and 
matched each item with terms in SNOMED CT. According to the query result, 4,243 
items in the custom dictionary were unique and 3,060 items overlapped with 
SNOMED CT. This evaluation showed that around 58% of the custom dictionary 
items are newly introduced as a lexicon resource. This is significantly high and 
should not be overlooked. Table 8 shows number of unique item for different types of 
n-gram in the custom dictionary. 
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Table 8. Number of Unique Items in the Custom Dictionary 
Type of n-gram Number of Unique Item 
1 2168 
2 1299 
3 486 
4 159 
5 84 
6 32 
7 11 
8 3 
9 1 
Total 4,243 
 
 Second, the items in the custom dictionary and in SNOMED CT were 
matched with test data set to validate usefulness of custom dictionary for processing 
clinical trial data. A total 1,058 clinical trial studies from January 1, 2011, to January 
1, 2013 were collected from the CliniclTrial.gov and the subject eligibility criteria 
section was divided into two parts, inclusion criteria and exclusion criteria. These two 
data sets were pre-processed with tokenization, lemmatization, and stop word 
removal. All possible trigram and bigram combination were generated to match with 
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the proposed custom dictionary and SNOMED CT. The matching results for trigram 
and bigram are presented in Table 99 and Error! Reference source not found. 
 
Table 9. Trigram Matching 
Trigram Matching 
 
Number of 
Matched Items 
Using the 
Custom 
Dictionary 
Only 
Number of 
Matched Items 
Using 
SNOMED CT 
Only 
Number of 
Matched Items 
Using the Custom 
Dictionary and 
SNOMED CT 
Additional 
Number of 
Unique Items 
Matched by 
Custom 
Dictionary 
Inclusion Data 828 904 1,439 535 
Exclusion 
Data 
748 984 1,226 242 
Total 1,576 1,888 2,665 777 
 
Table 10. Bigram Matching 
Bigram Matching 
 
Number of 
Matched Items 
Using the 
Custom 
Dictionary 
Only 
Number of 
Matched Items 
Using 
SNOMED CT 
Only 
Number of 
Matched Items 
Using the Custom 
Dictionary and 
SNOMED CT 
Additional 
Number of 
Unique Items 
Matched by 
Custom 
Dictionary  
Inclusion Data 4,842 6,932 9,610 2,678 
Exclusion 
Data 
4,158 5,958 8,198 2,240 
Total 9,000 12,890 17,808 4,918 
 
 According to the matching results, the SNOMED CT matched most items 
which were expected since the size of SNOMED CT is much larger than the custom 
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dictionary in both trigram and bigram. However, the number of matched items by 
using both the custom dictionary and SNOMED CT is greater than the number of 
matched items using SNOMED CT only. As shown in Table 9, 777 additional trigram 
matches were done by adding custom dictionary to SNOMED CT only match. This 
represents a 41% increase over SNOMED CT only match. Similarly as shown in 
Table 10, 4,918 additional bigram matches were done by adding custom dictionary to 
SNOMED CT only match. This represents a 38.6% increase over SNOMED CT only 
match. Thus, custom dictionary significantly increases the size of matches. 
 
2.6. Discussion 
 One of the most time consuming and high labor cost tasks in text mining 
research is the creation, compilation, and customization of the necessary lexicons 
(Jonnalagadda et al., 2013). Lexical resources are requisite to improve the 
performance of text mining, especially in NER. For the healthcare informatics 
researchers, it is required to implement modularized systems that cannot be 
generalized, therefore the building of customized lexical resources is needed for these 
highly specific systems (Stanfill et al., 2010). 
 This research has attempted to build a domain-specific lexicon focusing on 
breast cancer and has shown the semi-automated dictionary building process. The 
evaluations for breast cancer domain-specific dictionary using the clinical trial subject 
eligibility documents revealed that even though the total number of matched items 
using the custom dictionary is than the number of matched items using SNOMED 
CT, about 30% of matched items using the custom dictionary and SNOMED CT were 
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derived from the custom dictionary. This shows the importance of the domain 
specific dictionary and expert knowledge in lexicon resources. 
 There is no research that is free from limitation. First, coverage rate of 
domain-specific dictionary is relatively low. The domain-specific dictionary included 
limited online sources. Thus, if more extensive resource such as NCI Thesaurus is 
included in future research, it will result in better performance. The evaluation of this 
research only calculated the matched terms with test data set. If an annotated data as 
gold standard is available, more sophisticated evaluation metrics such as precision, 
recall, and F-measure could be included. In future research, with expert’s annotation 
for test data set, the most popular performance measures in information retrieval, 
accuracy, precision, recall, and F-measure could be evaluated. 
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CHAPTER 3 
Essay 2: Clustering Clinical Trials Using  
Semantic-Based Feature Expansion 
 
 
“The problems are solved, not by giving new information,  
but by arranging what we have known since long.” 
Ludwig Wittgenstein 
 
3.1. Introduction 
 The subject eligibility criteria section is one of the essential parts of clinical 
research protocols since it specifies the inclusion and exclusion characteristics of 
clinical research participants. Since clinical trial protocols and result data have been 
digitized and made publicly available by the National Institutes of Health (NIH), 
there has been an increasing need for developing novel approaches that exploit such 
an invaluable resource. However, there are several challenges to acquiring 
meaningful knowledge from an unstructured data source (Bollier, 2010). 
 One of the salient issues in data analysis is information overload. When 
searching relevant clinical trials in the one of largest online clinical trial repositories, 
ClinicalTrials.gov, which includes more than 190,000 clinical trial studies, the same 
information overload problem was encountered. Many scholarly methods such as 
EmergingMed, SearchClinicalTrials.org, and TrialX application have been developed 
to address this problem. Although a large number of studies have been made on 
narrowing the clinical trial search scope, they required users to create complex 
queries (Hao, 2014). 
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 An alternative option for a query-based clinical trial search is a case-based 
search by clustering trials, which can identify and suggest similar trial to an example 
trial (Hao, 2014). This approach can alleviate user burden to create complex query 
and can be useful for multiple usage cases. Clinical trial participants, clinical trial 
investigators, and meta-analysis researchers can benefit from the case-based search 
approach (Hao, 2014). To support case-based clinical trial search, it is necessary to 
develop an automated method for identifying and grouping semantic classes that 
belong to clinical trial subject eligibility criteria. 
 Interpretation of a subject eligibility section by means of a computer has 
received considerable attention for its promising applications in clinical trial research, 
especially in automatically matching patients to clinical trial studies (Luo, 2010).  
Inducing sematic classes from text data is an efficient way to understand text data and 
it is required to induce semantic classes from clinical trial eligibility criteria to 
understand that. Clustering is a popular solution for inducing semantic classes for 
various applications, such as ontology development, content organization, and 
thesaurus construction (Cheng et al., 2004; Pratt and Fagan, 2000; Lin, 1998).  
 In this research, we present a novel approach for reducing clinical trial 
information search space, which uses the result of hierarchical clustering with the n-
gram model and semantic-based feature expansion technique. 
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3.2. Background Literature 
 Table 11 presents the selected research on clinical trial using NLP and text mining. 
Table 11. Selected Research on Clinical Trial using NLP and Text Mining 
Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Tianyong Hao et 
al. 
Journal of 
Biomedical 
Informatics 
(2014) 
Clustering clinical trials 
with similar eligibility 
criteria features 
Identify and cluster 
clinical trials with 
similar eligibility 
features. 
Center-based 
clusters 
From 
ClinicalTrials.
gov 
useful for clinical 
trial eligibility 
criteria designs and 
for improving 
clinical trial 
recruitment 
S.W. Tu et al. 
Journal of 
Biomedical 
Informatics, 
(2011) 
A practical method for 
transforming free-text 
eligibility criteria into 
computable criteria 
Creating computer-
interpretable 
languages for 
eligibility criteria 
ERGO annotations 
1000 
eligibility 
criteria 
randomly 
drawn from 
ClinicalTrials.
gov 
incrementally 
capturing the 
semantics of free-
text eligibility 
criteria 
Guoqian Jiang, 
Harold R. Solbrig, 
Christopher G. 
Chute 
Journal of 
Biomedical 
Informatics 
(2011) 
Quality evaluation of cancer 
study Common Data Elements 
using the UMLS Semantic 
Network 
Relationship 
between 
terminological 
annotations and the 
UMLS Semantic 
Network (SN) that 
can be exploited to 
improve those 
annotations 
UMLS SN 
caDSR CDE 
Browser 
the UMLS SN 
based profiling 
approach is feasible 
for the quality 
assurance and 
accessibility of the 
cancer study 
CDEs 
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Authors  Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Boland MR, 
Miotto R, Gao J, 
Weng C, 
Methods of 
Information in 
Medicine(2013) 
Feasibility of Feature-based 
Indexing, Clustering, and 
Search of Clinical Trials on 
ClinicalTrials.gov: A Case 
Study of Breast Cancer Trials 
    
Luo Z, Yetisgen-
Yildiz M, Weng C, 
Journal of 
Biomedical 
Informatics 
(2011) 
Dynamic Categorization of 
Clinical Research Eligibility 
Criteria by Hierarchical 
Clustering 
    
Luo Z, Johnson 
SB, Weng C, 
Proc of AMIA 
2010 Fall 
Symposium 
Semi-Automatic Induction of 
Semantic Classes from Free-
Text Clinical Research 
Eligibility Criteria Using 
UMLS 
    
Weng C, Wu X, 
Luo Z, Boland M, 
Theodoratos D, 
Johnson SB 
Journal of the 
American 
Medical 
Informatics 
Association, 
(2011) 
EliXR: An Approach to 
Eligibility Criteria Extraction 
and Representation 
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3.3. Background 
Unified Medical Language System (UMLS) 
 UMLS was initiated in 1989 by the National Library of Medicine (NLM), which 
continues to maintain it. It is an attempt to fill the gap among the medical vocabularies 
from heterogeneous sources. The purpose of UMLS is to facilitate the development of 
computer systems that deal with the semantics of the language of biomedicine and health. 
NLM provides system developers with the UMLS Knowledge Sources (database) and 
related software applications (programs) for building healthcare information systems that 
create, process, retrieve, integrate, and aggregate biomedical and health data, as well as 
for use in academic research (Kohler 2008; 
http://www.nlm.nih.gov/pubs/factsheets/umls.html). 
 UMLS consists of three knowledge sources, which are the Metathesaurus, the 
Semantic Network, and the SPECIALIST Lexicon. Moreover, the three knowledge 
sources comprise several tools that facilitate the use of UMLS. 
 
Metathesaurus 
 The Metathesaurus is a very large, multipurpose, and multilingual vocabulary 
database that is organized by concepts. The current release contains more than 1.5 million 
biomedical terms from over 150 different sources. Synonymous terms are clustered 
together to form a concept. For example, "breast cancer," "breast tumor malignant," and 
"malignant neoplasm of breast" belong to the same UMLS concept. The concept unique 
identifier (CUI) for "breast cancer" is C0006142.  
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 There are various types of relationships that link concepts to other concepts. Inter-
concept relationships are not only inherited from the vocabulary sources but are also 
created by the Metathesaurus editors. All concepts in the Metathesaurus are assigned to at 
least one semantic type from the Semantic Network to keep consistent categorization at 
the general level depicted in the Semantic Network. 
 
Semantic Network 
 The main purpose of the Semantic Network is to provide a consistent 
categorization of all concepts stored in the Metathesaurus and information about a set of 
basic semantic types or categories. The Network contains 133 semantic types and 54 
relationships. There are major groupings of semantic types under topics such as 
organisms, anatomical structures, biologic function, chemicals, events, physical objects, 
and concepts or ideas. The scope of the UMLS semantic types is quite wide; therefore, it 
permits the semantic categorization to include a wide range of terminologies over 
multiple domains. 
 The Semantic Network is organized using a directed graph, where the semantic 
types represent the nodes and the relationships among them are the edges. Figure 4 
illustrates a portion of the Network. The semantic type "Biologic Function" has two 
children, "Physiologic Function" and "Pathologic Function," and each of these in turn has 
several children. Each child and parent in the hierarchy is linked by an "is-a" link. Figure 
5 illustrates a portion of the hierarchy for Network relationships. The "affects" 
relationship has six children, including "manages", "treats," and "prevents." Figure 6 
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shows a portion of the Semantic Network illustrating the relations, either hierarchical or 
associative, that exist between semantic types. 
 
 
Figure 4. A Portion of the UMLS Semantic Network: “Biologic Function” Hierarchy  
(UMLS Reference Manual, 2009) 
 
 
Figure 5. A Portion of the UMLS Semantic Network: “Affects” Hierarchy  
(UMLS Reference Manual, 2009) 
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Figure 6. A Portion of the UMLS Semantic Network: Relations  
(UMLS Reference Manual, 2009) 
 
SPECIALIST Lexicon and Lexical Tools 
 The SPECIALIST Lexicon is a general English lexicon including many 
biomedical vocabularies, and the Lexical Tools are designed to resolve the high degree of 
variability in natural language. The syntactic, morphological, and orthographic 
information for each term in the Lexicon is recorded by the SPECIALIST NLP system. 
The inflected forms of words or terms are appropriately considered instances of the same 
word. 
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3.4. Research Method 
 Figure 7 shows the steps of clinical trial clustering process using UMLS. First, I 
collected clinical trial information for breast cancer from ClinicalTrial.gov and parsed 
original XML format files. Next, only eligibility criteria section from clinical trial was 
extracted and pre-processed using tokenization, lemmatization, and stop word removal. 
Breast cancer specific dictionary and UMLS Metathesaurus were used for finding n-gram 
terms and semantic feature expansion. Agglomerative hierarchical clustering algorithms 
were applied to create clusters for the inclusion and exclusion data set and then 
intersectional clusters were derived. Finally, a label for intersectional cluster was created. 
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Figure 7. Steps for Clinical Trial Clustering Using Domain-Specific Dictionary and UMLS 
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3.4.1. Data Set 
 I collected the clinical trials from ClinicalTrials.gov, which is a registry and 
results database of publicly and privately supported clinical studies of human participants 
conducted around the world. I used the search term "breast cancer" to limit clinical trials 
to only the breast cancer domain and then collected three years of data from January 1, 
2010, to January 1, 2013. The total number of clinical trials collected is 1,660, all 
information on the trials were downloaded as a collection of individual Extensible 
Markup Language (XML) format files. XML is a markup language that defines a set of 
rules for encoding a document in a format that is both human-readable and machine-
readable. The World Wide Web Consortium (W3C) produces the specifications for XML 
1.0 and XML and has come into common use for the interchange of data over the Internet 
(http://en.wikipedia.org/wiki/XML). 
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 Figure 8 shows a sample of an original clinical trial XML document. 
 
Figure 8. Sample of Original Clinical Trial XML Document (NCT01483196.xml) 
 
 To parse an XML document and remove unnecessary tags, I developed a custom 
parser using the Ruby programming language. All XML tags metadata were removed and 
only the <eligibility> - <criteria> - <textblock> section was extracted. Subject eligibility 
criteria text was in a free text format and could be divided by two opposite criteria: 
“Inclusion” and “Exclusion.” I separated the subject eligibility criteria text block based 
on the key word “Inclusion criteria” and “Exclusion criteria.” There were several upper 
and lower case variations in the keyword such as “INCLUSION CRITERIA,” “inclusion 
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criteria,” and “inclusion Criteria.” The regular expression was used to capture all letter 
case variations. Once the eligibility criteria text was divided into two sections, all key 
words representing inclusion and exclusion were removed by the pre-processing step. 
Table 12 presents a sample of a criteria section extracted from the clinical trial id 
NCT0506700. The inclusion criteria set and exclusion criteria set were managed 
separately. The gender and age range were basic structured eligibility criteria that gave 
significant information during the matching process between the clinical trial and patient 
information. Thus, I extracted those two sections and included them with the data file 
naming rule. The naming rule for each eligibility criteria was <clinical trial ID_gender 
criteria_minimum age_maximu age>; as a result, the data file name for NCT050670 was 
modified to “NCT0506700_Female_18_NA.” This file name implied that females over 
age 18 were eligible to participate in the clinical trial NCT0506700. 
 
Table 12. Sample of Extracted Eligibility Criteria Text (ID; NCT0506700) 
Original criteria 
Inclusion Criteria:            1. Women 18 years of age or older            
2. Signed ICF            3. Women who have been histologically 
diagnosed with invasive ductal carcinoma or              invasive 
lobular carcinoma of the breast prior to surgery            4. 
Planning breast preservation            5. Patients undergoing 
lumpectomy (partial mastectomy) procedure          Exclusion 
Criteria:            1. Multicentric disease (histologically diagnosed 
cancer in two different quadrants of              the breast)            2. 
Neoadjuvant systemic therapy            3. All T4 tumors            4. 
Previous radiation in the operated breast            5. Prior surgical 
procedure in the same quadrant            6. Implants in the 
operated breast            7. Pregnancy            8. Lactation            
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9. Participating in any other investigational study for either drug 
or device which can              influence collection of valid data 
under this study 
Inclusion only 
            1. Women 18 years of age or older            2. Signed ICF            
3. Women who have been histologically diagnosed with 
invasive ductal carcinoma or              invasive lobular 
carcinoma of the breast prior to surgery            4. Planning 
breast preservation            5. Patients undergoing lumpectomy 
(partial mastectomy) procedure            
Exclusion only 
            1. Multicentric disease (histologically diagnosed cancer 
in two different quadrants of              the breast)            2. 
Neoadjuvant systemic therapy            3. All T4 tumors            4. 
Previous radiation in the operated breast            5. Prior surgical 
procedure in the same quadrant            6. Implants in the 
operated breast            7. Pregnancy            8. Lactation            
9. Participating in any other investigational study for either drug 
or device which can              influence collection of valid data 
under this study 
 
3.4.2. Pre-processing 
 For the first pre-processing step, I performed tokenization and lemmatization for 
the inclusion and exclusion data sets with Stanford CoreNLP, which is an integrated 
framework that provides a set of natural language analysis tools, including the part-of-
speech (POS) tagger, the named entity recognizer (NER), the parser, the co-reference 
resolution system, the sentiment analysis tools, and model files for analysis of English 
(http://nlp.stanford.edu/software/corenlp.shtml). The Stanford CoreNLP code is written 
in Java and licensed under the GNU General Public License (v2 or later) and requires 
Java 1.6 or higher version.  
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 The second pre-processing step was stop word removal. The Apache Lucene 
framework, a high-performance and full-featured text search engine library written 
entirely in Java, was used to remove stop words (http://lucene.apache.org/core/). Apache 
Lucene is an open source project available for free download. This study adopted Fox’s 
stop word list to cull all insignificant words in the data. 
 Table 13 presents a sample of the preprocessed inclusion and exclusion criteria 
text NCT01506700.  
Table 13. Sample of Preprocessed Inclusion and Exclusion Criteria 
Pre-processed 
Inclusion Criteria 
woman 18 year age older sign icf woman histologically 
diagnose invasive ductal carcinoma invasive lobular carcinoma 
breast prior surgery Planning breast preservation patient 
undergo lumpectomy partial mastectomy procedure 
Pre-processed 
Exclusion Criteria 
multicentric disease histologically diagnose cancer two different 
quadrant breast neoadjuvant systemic therapy t4 tumor previous 
radiation operate breast prior surgical procedure same quadrant 
implant operate breast pregnancy Lactation participate 
investigational study drug device influence collection valid 
datum under study 
 
3.4.3. Matching with Custom Dictionary 
 The domain-specific dictionary for breast cancer described in essay 1 was utilized 
to detect n-gram terms in the inclusion or exclusion criteria data set. In this first step, I 
identified all trigram combinations from the preprocessed data set and then matched each 
trigram term with the custom dictionary that has n-gram terms for the breast cancer 
domain. Once the trigram term was matched with the term in the custom dictionary, three 
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unigram tokens that consisted of the trigram were removed from the data. I replaced the 
space in the trigram with an underscore (_) to transform the trigram into the single token 
form because all identified trigram and bigram words should be considered as unigram 
terms to maintain the original n-gram form. After the trigram matching step was 
completed, all bigram combinations from the modified data set were drawn and matched 
with the custom dictionary. Table 14 shows all trigram combinations from NCT0506700 
and the results of the custom dictionary matching. From the pre-processed inclusion 
criteria presented in Table 14, I generated all trigram combinations that listed in Table 15. 
The first three tokens for clinical trial id ‘NCT01506700’ are ‘woman’, ‘18’, ‘year’, so 
trigram ‘woman 18 year’ was generated and this trigram compared with the custom 
dictionary. If the trigram ‘woman 18 year’ was found in the custom dictionary, the three 
unigram tokens, ‘woman’, ‘18’, and ‘year’ were removed from original data set and 
replaced with ‘woman_18_year’. Otherwise, the first three token was kept and the 
combination window for trigram slid to next token and generated second possible trigram 
combination ’18 year age’. All possible trigram combination from clinical trial id 
‘NCT01506700’ inclusion criteria were compared with the custom dictionary and found 
two trigram matches ‘invasive ductal carcinoma’ and ‘invasive lobular carcinoma’. 
 
Table 14. All Trigram Combinations from NCT01506700 and  
Results of the Custom Dictionary Matching 
Inclusion / 
Exclusion 
All Trigram Combinations 
Matching with  
The Custom Dictionary 
Inclusion 
Criteria 
woman 18 year 
18 year age 
year age older 
invasive ductal carcinoma 
invasive lobular carcinoma 
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age older sign 
older sign icf 
sign icf woman 
icf woman histologically 
woman histologically diagnose 
histologically diagnose invasive 
diagnose invasive ductal 
invasive ductal carcinoma 
ductal carcinoma invasive 
carcinoma invasive lobular 
invasive lobular carcinoma 
lobular carcinoma breast 
carcinoma breast prior 
breast prior surgery 
prior surgery Planning 
surgery Planning breast 
Planning breast preservation 
breast preservation patient 
preservation patient undergo 
patient undergo lumpectomy 
undergo lumpectomy partial 
lumpectomy partial mastectomy 
partial mastectomy procedure 
Exclusion 
Criteria 
multicentric disease histologically 
disease histologically diagnose 
histologically diagnose cancer 
diagnose cancer two 
cancer two different 
two different quadrant 
different quadrant breast 
quadrant breast neoadjuvant 
No Match 
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breast neoadjuvant systemic 
neoadjuvant systemic therapy 
systemic therapy t4 
therapy t4 tumor 
t4 tumor previous 
tumor previous radiation 
previous radiation operate 
radiation operate breast 
operate breast prior 
breast prior surgical 
prior surgical procedure 
surgical procedure same 
procedure same quadrant 
same quadrant implant 
quadrant implant operate 
implant operate breast 
operate breast pregnancy 
breast pregnancy Lactation 
pregnancy Lactation participate 
Lactation participate investigational 
participate investigational study 
investigational study drug 
study drug device 
drug device influence 
device influence collection 
influence collection valid 
collection valid datum 
valid datum under 
datum under study 
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 Table 15 shows all possible bigram combinations from NCT0506700 and the 
results of the custom dictionary matching. I generated all bigram combinations that listed 
in Table 15 from the pre-processed inclusion criteria presented in Table 14. The first two 
tokens for clinical trial id ‘NCT01506700’ are ‘woman’ and ‘18’, so bigram ‘woman 18’ 
was generated and then compared with the custom dictionary. If the bigram ‘woman 18’ 
was found in the custom dictionary, the two unigram tokens, ‘woman’ and ‘18’ were 
removed from original data set and replaced with ‘woman_18’. Otherwise, the first two 
tokens were kept, and the combination window for bigram slid to next token and 
generated second possible bigram combination ’18 year’. All possible bigram 
combination from clinical trial id ‘NCT01506700’ inclusion criteria were compared with 
the custom dictionary and found one bigram match ‘invasive ductal carcinoma’ and 
‘invasive lobular carcinoma’. 
Table 15. All Bigram Combinations from NCT01506700 and  
Results of the Custom Dictionary Matching 
Inclusion / 
Exclusion 
All Bigram Combinations 
Matching with  
The Custom Dictionary 
Inclusion 
Criteria 
woman 18 
18 year 
year age 
age older 
older sign 
sign icf 
icf woman 
woman histologically 
histologically diagnose 
diagnose breast 
breast prior 
partial mastectomy 
59 
 
 
prior surgery 
surgery Planning 
Planning breast 
breast preservation 
preservation patient 
patient undergo 
undergo lumpectomy 
lumpectomy partial 
partial mastectomy 
mastectomy procedure 
Exclusion 
Criteria 
multicentric disease 
disease histologically 
histologically diagnose 
diagnose cancer 
cancer two 
two different 
different quadrant 
quadrant breast 
breast neoadjuvant 
neoadjuvant systemic 
systemic therapy 
therapy t4 
t4 tumor 
tumor previous 
previous radiation 
radiation operate 
operate breast 
breast prior 
prior surgical 
surgical procedure 
procedure same 
systemic therapy 
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same quadrant 
quadrant implant 
implant operate 
operate breast 
breast pregnancy 
pregnancy Lactation 
Lactation participate 
participate investigational 
investigational study 
study drug 
drug device 
device influence 
influence collection 
collection valid 
valid datum 
datum under 
under study 
 
3.4.4. Matching with the UMLS Semantic Network 
Semantic-Based Feature Expansion Using UMLS 
 Identifying optimal feature sets is crucial for improving the effectiveness of text 
analysis (Chung 2009). There are two main research approaches to identifying optimal 
feature sets for text analysis. The focus of the first approach is on feature selection and 
extraction from relatively large documents. Usually, studies with a large corpus are 
concerned with reducing feature sets efficiently to identify the optimal feature sets that 
improve performance. The second approach focuses on expanding feature sets to find the 
optimal feature set that enhances performance. This approach utilizes relatively small 
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feature sets from small size documents and expands the features sets by adding 
semantically related features (Chung, 2009).  
 Tso et al. (2003) proposed a method of feature expansion to resolve the data 
sparseness problem, which is one of the most serious obstacles in research on word sense 
disambiguation (WSD). The experiment of using a word sense identifier with a feature 
expansion resulted in more than double the precision improvement over the baseline 
approach alone (Tso et al., 2003). A prior study (Chung, 2009) showed that expanded 
feature sets containing synonymous relationships significantly improved the results of 
text categorization. When expanding feature sets with synonyms used on classifier 
names, the effectiveness of text categorization considerably improved, regardless of word 
sense disambiguation (Chung, 2009). Fisher and Roark (2007) incorporated feature 
expansion techniques into their sentence-ranking framework and achieved substantial 
gains over the baseline framework, which does not include feature expansion steps. 
 Document representation through the simple BOW vector space model has a few 
shortcomings such as ignoring term dependencies, structure, and ordering of the terms in 
documents. To overcome these issues, Khan (2010) proposed Semantics Based Feature 
Vector using Part of Speech (POS) tags to extracts the concept of terms in feature set. 
Also, he used WordNet to extracts co-occurring and associated terms. The proposed 
method outperformed the TF-IDF with BOW feature selection method for text 
classification. 
 There have been several attempts to incorporate semantic features from the 
WordNet lexical database to improve the predictive performance of the text classification 
model (de Buenaga Rodriguez et al., 1997; Scott and Matwin, 1998; Jensen and Marinez, 
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2000; Kehagias et al., 2003; Hotho and Bloehdorn, 2004; Rosso et al., 2004; Peng and 
Choi, 2005; Mansuy and Hilderman, 2006). The rationale behind this is that the features 
in the training set alone are not enough to build a good model for categorization. 
However, if we incorporate the word relationships from WordNet, a more accurate model 
may be possible. Most prior studies reported that incorporating semantic features results 
in a statistically signiﬁcant increase in accuracy (Mansuy and Hilderman, 2006).  
 The clinical trial eligibility criteria section is not a lengthy document but is a 
succinct description of clinical trial subject characteristics. Moreover, the contents in the 
clinical trial eligibility criteria are written by medical researchers, and the target audience 
are also medical experts; thus, the criteria usually include a large number of medical 
terms. For that reason, I incorporated synonymously related terms from the UMLS 
Semantic Network to expand feature sets based on semantic relatedness.  
 All trigram and bigram terms that were found in the custom dictionary were 
passed on to the next step to find synonyms from the UMLS Semantic Network. I created 
a custom query to find all synonymous relationships in the UMLS Semantic Network and 
then ran the custom query with each trigram and bigram term.  
 Table 16 shows the UMLS synonym matching results for each trigram and bigram 
term, and Table 17 shows the final feature set for clinical trial NCT01506700. 
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Table 16. UMLS Synonym Matching Result for NCT01506700 
Inclusion / 
Exclusion 
Trigrams and Bigrams 
Found in Custom Dictionary 
Matching UMLS Synonyms  
Inclusion 
Criteria 
invasive ductal carcinoma No Match 
invasive lobular carcinoma No Match 
partial mastectomy 
Subtotal mastectomy 
Segmental excision of breast 
Excision of part of breast 
Partial mastectomy 
Segmental resection of breast 
Segmental excision of breast  
Exclusion 
Criteria 
systemic therapy No Match 
 
Table 17. Final Feature Set for NCT01506700 
Inclusion 
woman 18 year age older sign icf woman histologically 
diagnose invasive_ductal_carcinoma 
invasive_lobular_carcinoma breast prior surgery Planning breast 
preservation patient undergo lumpectomy partial_mastectomy 
procedure Subtotal_mastectomy Segmental_excision_of_breast 
Excision_of_part_of_breast Segmental_resection_of_breast 
Exclusion 
multicentric disease histologically diagnose cancer two different 
quadrant breast neoadjuvant systemic_therapy t4 tumor 
previous radiation operate breast prior surgical procedure same 
quadrant implant operate breast pregnancy Lactation participate 
investigational study drug device influence collection valid 
datum under study 
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 To the best of my knowledge, there has been no study that applies the semantic-
based feature expansion technique to clinical trial clustering. This is the first study that 
adopts novel approaches that can improve text analysis performance for clinical trial 
subject eligibility clustering.  
 
3.4.5. Hierarchical Clustering 
 Classification and clustering are two different types of data mining problems 
(Dunham, 2003). Also, they are two typical examples of supervised and unsupervised 
data mining.  
 Given a set of objects that is partitioned into a finite set of classes, classification is 
the task of automatically determining the class of an unseen object, based typically on a 
model trained on a set of objects with known class memberships. Clustering is the 
process of grouping data objects together on the basis of the features they have in 
common. The objects are grouped into clusters with the objective of maximizing the 
intra-cluster similarity and the inter-cluster dissimilarity between objects. 
 Classification is supervised in that it typically requires labeled training data to 
train a classifier. The categorization or automatic classification of texts is the task of 
distributing a set of documents according to some common characteristics. The terms 
“categorization” or “classification” are used when dealing with the assignation of a 
document to a predefined classes or categories.  
 Clustering is unsupervised since it is performed on raw input data with no prior 
knowledge, or supervision, over method. Unsupervised classification or "clustering" is 
automatic and discovers latent (hidden) unlabeled classes. The term “clustering” 
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designates the creation of classes or groups (clusters) of a certain number of similar 
objects without prior knowledge. The classes are isolated from one another and are 
discovered automatically. A large number of unsupervised classification methods have 
been applied to textual documents (Amine et al., 2008). 
 Hierarchical clustering is the clustering in which the clusters do not simply make 
a partition of the set of objects, but the set of objects are organized into a tree hierarchy 
so that any child cluster is a subset of the parent cluster and the sibling clusters are 
disjoint. When applied to genomes, hierarchical clustering produces a biological 
taxonomy, which helps us to make sense of the enormous diversity of living organisms. 
In any organism, there are many different kinds of features to choose from, and in 
principle, all of them can be used. Unsupervised learning is one of the main strengths of 
the hierarchical clustering methodology, and its high performance becomes even more 
significant when compared to some supervised methods. 
 
Similarity Measure 
 Typically, the similarity between documents is estimated by a function calculating 
the distance between the vectors of these documents.  Two documents that are close 
according to this distance are regarded as similar. Several measures of similarity have 
been proposed (Jones and Furnas, 1987), including the following:  
 Cosine distance: 
cos , 
 = 	∑  ! × #$!(, )% ·  ! × #$!(, )% ‖‖( · ‖‖(  
 Euclidean distance: 
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Euclidean , 
 = 	)∑ , 
(*+  
 Manhattan distance: 
Manhattan, 
 = 	∑ ,, ,*+  
 
 The main purpose of this essay is to cluster clinical trials with semantic based 
feature expanded subject eligibility criteria. There are a number of clustering models 
based on connectivity, centroid, distribution, and other characteristics. In this experiment, 
the agglomerative hierarchical clustering model was adopted because it could show all 
the merging steps in the clustering process. To measure similarity between clinical trial 
subject eligibility, I adopted the cosine distance, which is one of the popular metrics for 
text analysis. 
 
3.5. Results 
 Before conducting the hierarchical clustering analysis, the scatter score for all 
clusters was calculated to determine the optimal number of clusters. Scatter score 
measures the degree of within-cluster scatter for the specified clusterings with the 
specified distance. The within-cluster scatter is simply the sum of the scatters for each set 
in the clustering. As the number of clusters increases, the within-cluster scatter decreases 
monotonically. Typically, this is used to determine how many clusters to generate by 
inspecting a plot of within-cluster scatter against the number of clusters and looking for a 
"knee" in the graph. 
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 Figure 9 shows the scatter score for the all inclusion criteria set and the "knee" 
point of the graph, which is 156. Therefore, the optimal number of inclusion criteria 
clusters is 156. 
 
 
Figure 9: Scatter Score for All Inclusion Criteria Clusters 
 
 Figure 10 shows the scatter score for the all exclusion criteria set and the ‘knee’ 
point of the graph, which is 168. Therefore, the optimal number of inclusion criteria 
clusters is 168. 
Knee Point 
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Figure 10: Scatter Score for All Exclusion Criteria Clusters 
 
 Based on the scatter score analysis, I generated 156 clusters for inclusion criteria 
and 168 clusters for exclusion criteria. Figure 11 shows the sample of two clinical trials 
inclusion criteria (NCT01642511 and NCT01668914) that clustered together at a low 
level because the similarity score is 1.0. Table 18 shows the original eligibility inclusion 
criteria of NCT01642511 and NCT01668914. 
 
Knee Point 
(168) 
69 
 
 
 
Figure 11. Tree of Hierarchical Clustering for NCT01642511 and NCT01668914 
 
Table 18. Original Text of Two Clinical Trials (NCT01642511 and NCT01668914) 
CT ID  NCT01642511 NCT01668914  
 Similarity Score =1.0 
Original 
Text 
 -  enlarged internal mammary nodes 
by imaging  
 -  enlarged internal mammary nodes 
by imaging  
 
 Figure 12 shows the sample of two clinical trials exclusion criteria 
(NCT01510964 and NCT01691144) that merged at a high level because the similarity 
score was 0.56. Table 19 shows the original eligibility exclusion criteria of 
NCT01510964 and NCT01691144. 
 
Figure 12. Tree of Hierarchical Clustering for Exclusion Criteria  
(NCT01510964 and NCT01691144) 
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Table 19: Original Text of Two Clinical Trials for Exclusion Criteria  
(NCT01510964 and NCT01691144) 
CT ID  NCT01510964  NCT01691144  
 Similarity Score =0.56 
Original 
Text 
-  presence of metastasis or 
relapse            -  severe mental 
deterioration  
-  comprehension difficulties of 
the Italian language.  
 -  Unability to fill out questionnaires 
(due to language or cognitive barriers)  
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 Table 20 shows other examples of case comparison by the inclusion criteria similarity score. 
Table 20. Example of Case Comparison 
Case No. Contents Case No. Contents Score 
NCT01619306 
Inclusion Criteria:            -  Patients with early 
stage breast cancer            -  Healthcare 
professionals caring for breast cancer patients            
-  Medical students /cancer researchers 
NCT01619514 
Inclusion Criteria:            -  Patients with breast 
cancer 
0.88 
NCT01506869 
Phase 1          Inclusion Criteria:            1. 
Age >= 40 years old            2. Gender: males 
and females            3. Provide written informed 
consent            4. Satisfactory compliance          
Phase 2          Inclusion Criteria:            1. 
Age >= 40 and =< 75 years old            2. 
Gender: males and females            3. Provide 
written informed consent            4. Satisfactory 
compliance          Exclusion Criteria:            1. 
History of cancer;            2. History of LADA 
and other autoimmunity diseases;            3. 
Acute diabetic complication, acidosis, etc;            
4. Moderate to severe liver, kidney 
dysfunction, i.e. ALT/AST > 2.5 times the 
upper              limit of normal range or Ccr < 
25ml/min;            5. Any other condition or 
major systemic diseases that the investigator 
feels would              interfere with trial 
participation or evaluation of results. 
0.09 
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NCT01526499 
Inclusion Criteria:            1. Females with age 
between 18 and 70 years old            2. ECOG 
performance between 0-1            3. Life 
expectancy more than 3 months            4. 
Histological proven unresectable recurrent or 
advanced breast cancer            5. No previous 
chemotherapy for metastatic breast 
cancer;suitable for monotherapy              
(Neoadjuvant or adjuvant docetaxel should be 
completed at least one year).            6. At least 
one measurable disease according to the response 
evaluation criteria in              solid tumor 
(RECIST1.1)            7. No anticancer therapy 
within 4 weeks            8. Adequate hematologic, 
hepatic, and renal function,No serious medical 
history of              heart, lung, liver and kidney            
9. Provision of written informed consent prior to 
any study specific procedures          Exclusion 
Criteria:            1. Pregnant or lactating women 
(female patients of child-bearing potential must 
have a              negative serum pregnancy test 
within 14 days of first day of drug dosing, or, if              
positive, a pregnancy ruled out by ultrasound)            
2. Women of child-bearing potential, unwilling 
to use adequate contraceptive protection              
during the course of the study            3. 
Treatment with an investigational product within 
4 weeks before the first treatment            4. 
Symptomatic central nervous system metastases            
NCT01526512 
Inclusion Criteria:            1. Females with age 
between 18 and 80 years old            2. ECOG 
performance between 0-3            3. Life 
expectancy more than 3 months            4. 
Histological proven unresectable recurrent or 
advanced HER2-negative breast cancer            
5. At least one previous therapy regimen 
(including endocrine therapy) for metastatic              
breast cancer;suitable for monotherapy 
(Neoadjuvant or adjuvant docetaxel should be              
completed at least one year).            6. At least 
one measurable disease according to the 
response evaluation criteria in              solid 
tumor (RECIST1.1)            7. No anticancer 
therapy within 4 weeks            8. Adequate 
hematologic, hepatic, and renal function,No 
serious medical history of              heart, lung, 
liver and kidney            9. Provision of written 
informed consent prior to any study specific 
procedures           10. Previous capecitabine is 
permitted, however, it should be completed at 
least 6              months.          Exclusion 
Criteria:            1. Pregnant or lactating women 
(female patients of child-bearing potential must 
have a              negative serum pregnancy test 
within 14 days of first day of drug dosing, or, if              
positive, a pregnancy ruled out by ultrasound)            
2. Women of child-bearing potential, unwilling 
to use adequate contraceptive protection              
0.97 
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5. Other active malignancies (including other 
hematologic malignancies) or other              
malignancies, except for cured nonmelanoma 
skin cancer or cervical intraepithelial              
neoplasia.            6. Patient having a history of 
clinically significant cardiovascular, hepatic,              
respiratory or renal diseases, clinically 
significant hematological and endocrinal              
abnormalities, clinically significant neurological 
or psychiatric conditions            7. Uncontrolled 
serious infection            8. Patients with bad 
compliance 
during the course of the study            3. 
Treatment with an investigational product 
within 4 weeks before the first treatment            
4. Symptomatic central nervous system 
metastases            5. Other active malignancies 
(including other hematologic malignancies) or 
other              malignancies, except for cured 
nonmelanoma skin cancer or cervical 
intraepithelial              neoplasia.            6. 
Patient having a history of clinically significant 
cardiovascular, hepatic,              respiratory or 
renal diseases, clinically significant 
hematological and endocrinal              
abnormalities, clinically significant 
neurological or psychiatric conditions            7. 
Uncontrolled serious infection            8. 
Patients with bad compliance            9. Patients 
lack of Dihydropyrimidine 
Dehydrogenase(DPD) 
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NCT01569802 
Inclusion Criteria:            -  Subject is female 
of any race and ethnicity            -  The subject 
is asymptomatic and presents for routine 
screening mammography and              chooses 
to have a combination 2D + 3D mammogram 
as her standard of care.          Exclusion 
Criteria:            -  Patient chooses standard 2D 
mammography over a combination 2D + 3D 
mammogram 
0.07 
NCT01558258 
Inclusion Criteria:            -  women diagnosed 
with early, resectable breast cancer (Stage 0, I, II, 
or III) prior              to age 50            -  have 
completed treatment with surgery, radiation, 
and/or chemotherapy at least 3              months 
previously.          Exclusion Criteria:            -  
have a breast cancer recurrence, metastasis, or 
another cancer diagnosis (excluding              non-
melanoma skin cancer            -  unable to commit 
to intervention schedule. 
NCT01627366 
Inclusion Criteria:            -  Female            -  21 
years of age or older            -  English- or 
Spanish-speaking            -  Diagnosis of ductal 
carcinoma in situ (DCIS) or Stage I, II, or III 
BC for the first              time            -  12 
months post-diagnosis            -  At least 1 
month post-chemotherapy completion          
Exclusion Criteria:            -  Previous cancer 
except non-melanomatous skin cancers or in 
situ non-breast cancers            -  Pregnant and 
lactating women            -  Patients receiving 
parenteral anti-cancer therapy, except 
trastuzumab            -  Clinically apparent 
cognitive or psychiatric impairment            -  
0.59 
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Participation in another research study            -  
Current treatment for another cancer            -  
Male 
NCT01569802 
Inclusion Criteria:            -  Subject is female 
of any race and ethnicity            -  The subject 
is asymptomatic and presents for routine 
screening mammography and              chooses 
to have a combination 2D + 3D mammogram 
as her standard of care.          Exclusion 
Criteria:            -  Patient chooses standard 2D 
mammography over a combination 2D + 3D 
mammogram 
0.01 
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3.5.1. Intersection of inclusion and exclusion clusters 
 Since the inclusion and exclusion subject eligibility criteria were mutually 
exclusive, the eligibility criteria section was divided into two sub-sections: inclusion 
criteria and exclusion criteria. The two data sets were pre-processed, matched with the 
custom dictionary and UMLS Metathesaurus, and clustered individually. However, to 
achieve completed clinical trial subject eligibility clusters, it was necessary to merge the 
two different cluster sets. 
 All the elements in each inclusion cluster were compared with all the elements in 
each exclusion cluster and new clusters were generated based on only the elements 
belonging to the same inclusion and exclusion clusters. Figure 13 presents an example of 
new cluster generation. For instance, clinical trials A, B, C, and D belong to the inclusion 
cluster Inc-I, and clinical trials A, B, E, D, and F belong to the exclusion cluster Exc-I. 
From this example, the new cluster Inc-I is created that includes only the common 
elements of the inclusion cluster Inc-I and the exclusion cluster Exc-I. More specifically, 
when we assume that one of the criteria in the inclusion cluster Inc-I is subject’s 
pregnancy and one of the criteria in the exclusion cluster Exc-I is subject’s breast 
feeding, the intersection cluster of the inclusion cluster Inc-I and the exclusion cluster 
Exc-I will have the eligibility criteria that include subjects who are pregnant but exclude 
those who are breastfeeding. 
 As mentioned before, the total number of inclusion clusters was 156 and the total 
number of exclusion clusters was 168. From these clusters, 596 intersection clusters were 
generated. Accordingly, the number of intersection clusters that had more than two 
instances was 117, and the number of intersection clusters with two or less than two 
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instances was 479. Table 21 presents the number of intersection clusters. The name for an 
intersection cluster was assigned by combining the ID of the inclusion cluster and the 
exclusion cluster. For example, the intersection cluster Inc(16)_Exc(130) had clinical 
trials that appeared in both inclusion cluster(16) and exclusion cluster(13). 
 
Table 21. Number of Intersectional Clusters 
 Number of Clusters 
Total number of intersection clusters 596 
Number of single-instance clusters 393 
Number of two-instance clusters 86 
Number intersection clusters  
having more than two instances 
117 
 
78 
 
 
 
Figure 13. Intersection Clusters of the Inclusion and Exclusion Clusters 
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3.6. Cluster labeling 
3.6.1. UMLS Synonym chunks 
Identifying most frequent synonym chunks in clusters 
 To identify the characteristics of clusters, I generated a label for each cluster.  
First, I counted all the synonym chunks that were used for the semantic feature expansion 
in inclusion and exclusion criteria from same intersection clusters. The most frequent 
synonym chunk of the inclusion and exclusion clusters was selected as the representative 
label for the intersection cluster. If the most frequent synonym chunk in the inclusion or 
exclusion cluster had been already selected for another intersection cluster, the second 
most frequent synonym chunk was selected. If multiple most frequent synonym chunks 
with the same frequency are found, all of the synonym chunks in the top frequency were 
selected for labeling. 
Next, I queried UMLS Metathesaurus with selected inclusion and exclusion 
synonym chunks to find the lowest concept unique identifier among synonyms. The CUI 
in UMLS is the concept unique identifier for a UMLS Metathesaurus concept to which 
strings with the same meaning are linked. The synonyms in chunks has their own CUI. 
To find unique name of each synonym chunk, I used lowest CUI in each synonym chunk. 
Then, all the lowest CUI concepts from UMLS Metathesaurus are merged and the 
‘|’ symbol is added between concepts as a delimiter. Also, ‘||’ is added to divide inclusion 
and exclusion synonym chunks.  
 Table 22 presents the proposed label for the intersection cluster 
Inc(16)_Exc(130). For the Inc(16)_ExC(13) cluster, the lowest CUI of the most frequent 
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synonym chunk in inclusion section is C0013216 and the note for C0013216 are 
‘Chemotherapy’ and ‘Drug therapy’. The lowest CUI of the most frequent synonym 
chunk in exclusion section is C0006141 and the notes for C0006141 are ‘Breast 
anatomy’, ‘Breast’ and ‘Breast structure’. The proposed label for Inc(16)_Exc(130) is 
merging the notes for these two sections, ‘CT - Chemotherapy|Drug 
therapy|Chemotherapy|DT - Drug therapy||Breast anatomy|Breast|Breast structure’. The 
proposed label means that representative inclusion criteria for intersection cluster 
Inc(16)_Exc(130) are ‘Chemotherapy’ and ‘Drug therapy’. The representative exclusion 
criteria for intersection cluster Inc(16)_Exc(130) are ‘Breast anatomy’, ‘Breast’ and 
‘Breast structure’. All the trials in intersection cluster Inc(16)_Exc(130) require 
‘Chemotherapy’ or ‘Drug therapy’ experience for patients as inclusion criteria, and the 
patient experienced ‘Breast anatomy’ should be excluded all trials in intersection cluster 
Inc(16)_Exc(130). 
 
Table 22. Proposed label for the cluster Inc(16)_Exc(130) 
Intersection Cluster ID Label 
Inc(16)_Exc(130) 
CT - Chemotherapy|Drug therapy|Chemotherapy|DT - 
Drug therapy||Breast anatomy|Breast|Breast structure 
 
 Table 23 shows the algorithm to generate labels for the intersectional clusters. 
First, all the UMLS synonym chunks were counted for all the inclusion and exclusion 
clusters. Second, the most frequent synonym chunk in each inclusion and exclusion 
cluster was selected as a candidate for label. If there were more than two synonym 
chunks in one cluster in the same frequency, all the synonym chunks were selected. If the 
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most frequent synonym chunk had been already selected for another cluster, the second 
most frequent synonym chunk was the selected candidate. Third, the synonym chunk for 
inclusion and exclusion was merged to generate the full label. If inclusion and exclusion 
synonym chunks were the same, I selected the second most frequent synonym chunk for 
the exclusion cluster. 
 
Table 23. Pseudo Code for generating cluster label 
Function GenerateIntersectionClusterLabel(ClusterID) : returns ClusterLabel 
Begin 
 Set ClusterLabel to null 
 Set ClinicalTrials to null 
 Set SynonymInclusion to null 
 Set SynonymExclusion to null 
 Set MostFrequentSynonymsInInclusion 
 Set MostFrequentSynonymsInExclusion 
 Set SynonymCount to 0 
 Create Queue, Q 
 Query DB AllClinicalTrials in ClusterID 
 Add AllClinicalTrials to Q 
 While Q is not empty 
  De-queue AllClinicalTrials CT from Q 
  For each CT in AllClinicalTrials 
   Query DB Synonym in CTInclusion 
   Count SynonymInclusion 
   For each Synonym in CTInclusion 
    If CountIncSynonym >= MostFrequentSynonymsInInclusion  
    and LowesetCUIIncSynonym is not exist in Label list 
     MostFrequentSynonymsInInclusion = SynonymInclusion 
     Qeury DB newLowestCUI in UMLS 
     Add ClusterLabel 
    Else If 
     Break 
    End If 
   Next 
   Query DB Synonym in CTExclusion 
   Count SynonymExclusion 
   For each Synonym in CTExclusion 
    If CountExcSynonym >= MostFrequentSynonymsInExclusion
    and LowesetCUIExcSynonym is not exist in Label list 
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     MostFrequentSynonymsInExculision = SynonymExclusion 
     Qeury DB newLowestCUI in UMLS 
     Add ClusterLabel 
    Else If 
     Break 
    End IF 
   Next 
  Next 
 End While 
 Return ClusterLabel 
End 
 
 
 The clinical trial NCT01202851 belongs to the intersection cluster 
Inc(16)_Exc(130). Table 24 presents the original text of the subject eligibility section in 
NCT01202851; it has ‘adjuvant radiation’ in the inclusion criteria and ‘surgical 
treatment’ in the exclusion criteria, both corresponding to the proposed label. 
 
Table 24. Subject Eligibility of NCT01202851 
CT ID Subject Eligibility Text 
NCT01202851 
Inclusion Criteria:            1. Women with stage 0 - III 
breast cancer who will be undergoing daily adjuvant              
radiation for 4-6 weeks (patients only).            2. 18 
years of age or older (patient and spouse/partner).            
3. Able to read, write, and speak English or Spanish 
(patient and spouse/partner).          Exclusion Criteria:            
1. Patients who have any major psychiatric diagnoses 
(e.g., schizophrenia, bipolar              disorder).            2. 
Patients who have not undergone any surgical 
treatment for their cancer.            3. Patients with 
extreme mobility issues (e.g., unable to get in and out of 
a chair              unassisted).            4. Patients who have 
practiced yoga or taken yoga classes in the year prior to 
study              enrollment or who are currently engaged 
in a regular mind-body practice 
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3.7. Discussion 
 The broad objective of this work was to group and summarize clinical trial subject 
eligibility using a hierarchical clustering approach. This essay has also presented a 
framework for clustering clinical trial and labeling clusters. 
 In this research, I examined 1,660 breast cancer clinical trials and derived 596 
intersectional clusters. Also, I generated a label for each cluster to identify the 
characteristics of the cluster. The full text information of clinical trial studies were 
collected from ClinicalTrials.gov, and the original XML format documents were parsed 
with the author-developed parser. The subject eligibility section was extracted from the 
parsed documents and it was divided into two data sets for inclusion and exclusion 
criteria.  
 The agglomerative hierarchical clustering algorithm with cosine similarity metric 
was used to generate two sets of clusters, one for inclusion and the other for exclusion 
criteria; sets and intersection clusters were derived from those two cluster sets. The 
cluster labels were generated based on the most frequent UMLS synonym chunks in each 
inclusion and exclusion cluster to understand the characteristics of clusters. 
 While healthcare and IS researchers have made substantial progress in clustering 
clinical trial subject eligibility, little has been done to examine the semantic feature 
expansion technique in the healthcare domain and the contrary characteristics of 
inclusion and exclusion criteria. Inclusion criteria should be found and exclusion criterial 
should not be found in patient records. 
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 This essay has also made practical contributions by providing groups of similar 
clinical trials that can reduce a physician’s search space to find relevant trials to help 
clinical trial research as well as to provide alternative treatment to terminal disease 
patients. 
The clusters can also be utilized by initiators of new clinical trial study for finding 
similar trials currently in progress. When a primary investigator starts a new clinical 
research study, he or she is required to review all the relevant prior clinical studies. The 
clusters from this study can reduce the cost and effort for future clinical trial researchers 
by providing clinical trial clusters that have been labeled with the main features. 
Furthermore, the total number of clinical trials is increasing, and research in the 
healthcare domain is becoming more competitive. A clinical study usually requires a 
huge amount of resources with respect to financial support, expert involvement, and 
subject participation. Therefore, repeating the same type of clinical study should be 
avoided; each study should have its unique contributions. The clusters from this research 
could be exploited for finding research on similar topics and help to screen research 
topics that have been already conducted by other researchers. Furthermore, when a new 
trial study is proposed, the primary investigator usually estimates the required number of 
subjects. The cluster information can provide a similar trial group, and the primary 
investigator can use that to identify other trials that are looking for similar patients. In this 
vein, clinical trial cluster information enables for researchers to estimate probability of 
successful recruitment of required number of participants. 
 There are several ways in which future research could strengthen the results of 
this study. First, this research was confined to the breast cancer domain. Future studies 
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could investigate the proposed framework in the context of different kinds of diseases. I 
used the hierarchical clustering algorithm and applied the cosine theta as the document 
similarity metric. However, prior studies have proposed different approaches for 
clustering and document similarity metrics. For example, Latent Dirichlet allocation 
(LDA), latent semantic indexing, independent component analysis, probabilistic latent 
semantic indexing, non-negative matrix factorization, and Gamma-Poisson distribution 
techniques have been used in bioinformatics research. These new techniques could be 
applied in future research. 
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CHAPTER 4 
Essay 3: Automatic Matching Process of  
Clinical Trials Subject Recruitment 
 
 
“With enough information, it is almost impossible ‘not’ to predict people's action.” 
Idries Shah 
 
4.1. Introduction 
 About 85% of people with cancer were either unaware or unsure that participation 
in clinical trials was an option, although about 75% of these people said they would have 
been willing to enroll had they known it was possible (Harris Interactive, 2001). Previous 
research by UC Davis Cancer Center (UC Davis Cancer Center, 2001) investigators, 
published in 2001 in the Journal of Clinical Oncology, found that both doctors and 
patients sometimes hold misconceptions that can discourage enrollment in clinical trials. 
In the UC Davis Cancer Center study, more than one third of the doctors declined to refer 
patients to clinical trials, mistakenly believing that no trials were available. In reality, 
more than 150 clinical trials were available during the study period.  
 Another common barrier of clinical trial participation is distrust or suspicion 
about research. This is despite the fact that many investigational treatments are at least as 
effective as conventional therapy, and cancer patients who participate in clinical trials 
frequently have higher survival rates than those who receive standard care (UC Davis 
Cancer Center, 2001). Because of this unwarranted distrust or suspicion, four out of ﬁve 
clinical trials are delayed, and 50% of the delays are due to participant recruitment 
challenges (Patel et al., 2010).  
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 These low rates represent a significant barrier to speeding progress in cancer 
treatment by delaying the dissemination of new therapies. Low participation in clinical 
trials is a critical issue in healthcare research, where participation rates range between 5% 
and 10% for most trials (Patel et al., 2007). In the domain of oncology, for example, 
fewer than 3% of potentially eligible patients enroll in clinical trials, and patient 
enrollment for clinical trials is as low as 2% of the patient recruitment goal (Embi et al., 
2005).  
 Although the cost of running trials is now approaching 30% of pharmaceutical 
companies’ entire drug development budgets, 75% of patient studies fail to make their 
timelines, often causing expensive delays in regulatory approval and market launch. Also, 
testing on humans is a sensitive and a difficult issue as it involves many legal and ethical 
issues.  Difficulties in patient recruitment are the major reason for failure of clinical 
research (Spilker and Cramer, 1992).  
 Low and slow recruitment has serious negative impacts on the translation of the 
clinical trial results. It could produce inadequate statistical analyses of outcomes, lead to 
premature closure of trials, delay trial duration, incur higher costs of drug production, and 
cause loss of accreditation of the research institution that performs these studies 
(Penberthy et al. 2010). 
 Patient and physician factors can also be barriers to the enrollment in clinical 
trials (Breitfeld et al. 1999). Patient factors include lack of access to a healthcare institute 
offering clinical trials, economic and social barriers, and attitudes and beliefs. Among the 
diverse reasons physicians may fail to offer clinical trial participation to patients is lack 
of time. For example, to determine whether new patients may be eligible for a clinical 
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trial, physicians need to search multiple clinical trial repositories and read through the 
eligibility sections of several protocol documents. Physicians who participate in a busy 
oncology practice may find that they do not have sufficient time to do this and identify 
eligible subjects efficiently.  Their lack of time for these activities, which may interrupt 
the flow of patients, constitutes a substantial barrier to trial enrollment.  They may also 
simply forget to offer and enroll patients in possible trials. 
 Determining the eligibility of every patient is the first step in assuring adequate 
and unbiased clinical trial research. Yet, not all eligible patients are evaluated or invited 
to participate in a clinical trial despite the fact that patients who are offered a trial are 
likely to participate (Albrecht, 2008). One of the major impediments to participation is 
that this process of matching a patient to a clinical trial is manual and physician-driven. 
Traditionally, in this process, clinical trial research staff manually review multiple 
clinical data sources from patient medical records and match them with subject eligibility 
criteria. Eligible patients are often missed by this manual review process (Penberthy, 
2010). Thus, helping identify potentially eligible subjects increases the likelihood of 
patient participation in a clinical trial and is critical to the issue of under-representation. 
 In this essay, I propose a novel framework for clinical trial subject recruitment 
using NLP and text mining techniques for automating the clinical trial and subject 
matching process, which is currently labor intensive and error prone. The proposed 
approach could be very helpful for expediting and improving the clinical trial subject 
recruitment process. 
 The rest of the chapter is organized as follows. The literature review that serves as 
the overview of research stream in patient and clinical trial matching is presented in 
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section 4.2. Document similarity measurement techniques underlying the patient and 
clinical trial matching process, as well as the entire research framework, are presented in 
sections 4.3 and 4.4. Section 4.5 presents the matching and evaluation results. Section 4.6 
discusses the implications, limitations, and future directions of this research. 
 
  
9
0
 
4.2. Background Literature 
 Table 25 presents the selected research on matching clinical trials and patient information. 
Table 25. Selected research on matching clinical trials and patient information 
Authors Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Patel et al. 
IBM Research 
(2007) 
Matching Patient Records to 
Clinical Trials Using 
Ontologies 
Case study for 
clinical trial subject 
selection using 
ontologies and 
semantic 
technology 
 
SNOMED CT, 
One year patient 
data from 
Columbia 
Medical Center 
 
Patel et al. Elsevier (2012) 
TrialX: Using semantic 
technologies to match patients 
to relevant clinical trials based 
on their Personal Health 
Records 
TrialX, a consumer-
centric tool that 
matches patients to 
clinical trials 
   
Embi et al. 
American 
Medical 
Association 
(2005) 
Effect of a clinical trial alert 
system on physician 
participation in trial 
recruitment 
Evaluation of 
electronic health 
record based 
clinical trial alert 
system 
 
4 month 
intervention with 
114 physicians 
The CTA 
intervention was 
associated with 
significant 
increases in 
physicians’ referrals 
and enrollments 
Breitfeld et al. 
Journal of the 
American 
Medical 
Informatics 
Association 
(1999) 
Pilot Study of a Point-of-use 
Decision Support Tool for 
Cancer Clinical Trials 
Eligibility 
Development of 
point-of-use 
portable decision 
support tool (DS-
TRIEL) to 
automate this 
matching process 
 
pilot-test with 
academic medical 
oncologist 
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Authors Journal Title 
Topic / Research 
Question 
Theory/ Model Data 
Finding / 
Implication 
Brigitte Séroussi 
and Jacques 
Bouaud 
Artificial 
Intelligence in 
Medicine (2003). 
Using OncoDoc as a 
computer-based eligibility 
screening system to improve 
accrual onto breast cancer 
clinical trials 
Development of 
OncoDoc decision 
support system 
designed to provide 
best therapeutic 
recommendations 
for breast cancer 
patients 
  
Significantly 
improved physician 
compliance and 
enhanced physician 
awareness of open 
trials. 
Penberthy et al. 
Contemporary 
Clinical Trials 
(2010) 
Automated matching software 
for clinical trials eligibility: 
Measuring efficiency and 
flexibility 
A pilot project 
evaluating the 
efficiency, 
flexibility, and 
generalizability of 
an automated 
clinical trials 
eligibility screening 
tool  
 
5 different 
clinical trials and 
clinical trial 
scenarios. 
Automation offers 
an opportunity to 
reduce the burden 
of the manual 
processes required 
for CT eligibility 
screening 
Fink et al. 
Artificial 
Intelligence in 
Medicine (2004) 
Selection of patients for 
clinical trials: an interactive 
web-based system 
Development of a 
web-based expert 
system that assigns 
cancer patients to 
clinical trials 
 
187 past patients 
and 74 current 
patients for 
Knowledge base 
261 breast-cancer 
patients for test 
 
Korkontzelos et 
al. 
BMC Medical 
Informatics and 
Decision Making 
(2012) 
ASCOT: a text mining-based 
web-service for 
efficient search and assisted 
creation of clinical 
trials 
ASCOT, clinical 
trial search and 
creation tool. 
 
1800 clinical 
trials 
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 There has been limited research on the topic of clinical trial and patient matching 
process. Korkontzelos et al. (2012) presented ASCOT (Assisting Search and Creation Of 
Clinical Trials), a clinical trial search application that employs text mining technology, 
clustering, and term extraction algorithms.  
 Patel et al. (2010) published an article on the clinical trial and patient matching 
process. In that paper, they introduced TrialX, a consumer-centric tool that matches 
patients to clinical trials by extracting Personal Health Records (PHR) from Microsoft 
HealthVault (MHV) and Google Health (GM), and linking patients to the most relevant 
clinical trials using semantic web technologies. 
 Penberthy et al. (2010) evaluated the efficiency, flexibility, and generalizability of 
a clinical trials eligibility screening tool with five different clinical trials. The results of 
their study demonstrated that the automated tool could reduce the time and cost of the 
manual processes required for clinical trial eligibility screening and assure clinical trial 
participation opportunity. During the study period in evaluating patients for eligibility by 
research staff, there was a substantial total savings ranging from 165 hours to 1,329 
hours. The ratio of mean staff time for identifying eligible patients ranged from 0.8 to 
19.4 for the manual versus the automated process. 
 In 2007, Patel et al. tried to formulate the clinical trial and patient matching 
process as a problem of semantic retrieval. They focused on the applicability of 
SNOMED CT ontologies, which define classes of disorders, drugs, and organisms. The 
case study, conducted with one year of anonymized patient records from Columbia 
University Medical Center, reported that using an ontology to automate the matching 
process is feasible and practical. However, that research focused only on the ontology-
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based mapping. No text mining or NLP techniques were examined for the matching 
process. 
 Embi et al. (2005) investigated the effects of an electronic health record (EHR)-
based clinical trial alert (CTA) system in selected outpatient clinics of a large US 
academic healthcare system. CTA was tested during the subsequent 4-month intervention 
period when a patient’s EHR data met selected trial criteria. One hundred fourteen 
physicians practicing at selected EHR-equipped clinics participated in the study. The 
researchers compared the number of physicians participating in recruitment and their 
recruitment rates before and after CTA intervention. The results of the study showed that 
CTA intervention was associated with significant increases in the number of physician 
referrals and enrollment. However, Embi et al.’s research only focused on the evaluation 
of CTA intervention, and the clinical trial eligibility matching was conducted by the 
trial’s principal investigator. 
 Breitfeld et al. (1999) developed a point-of-use portable decision support tool 
(DS-TRIEL) to automate the matching process. A two-level hierarchic decision 
framework was used for the identification of eligible subjects for two open breast cancer 
clinical trials. 
 Séroussi and Roland (1998) developed OncoDoc, which is a decision support 
system designed to provide the best therapeutic recommendations for breast cancer 
patients. OncoDoc is a browsing tool of a knowledge base, structured as a decision tree, 
which allows physicians to control the contextual instantiation of patient characteristics 
to build the best formal equivalent of an actual patient. It provides either evidence-based 
therapeutic options or relevant patient-specific clinical trials. 
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 Fink et al (2004) developed a rule-based expert system that helps assign patients 
to clinical trials. The experiment results showed that their system can increase the 
efficiency of the patient selection process. 
 There have been several research studies that developed expert systems for 
helping select clinical trials for cancer and AIDS patients. Musen et al. (1996) built a 
rule-based system, called EON, that matched AIDS patients to clinical trials.  
 Ohno-Machado et al. developed the AIDS2 system, which matched AIDS patients 
to clinical trials (Ohno-Machado et al., 1993). The integrated logical rules with Bayesian 
networks was used for the AIDS2 system, and the system helped decision-making with 
incomplete data and to quantify the decision quality. 
 Bouaud et al. created ONCODOC, a cancer expert system that suggested 
alternative clinical trials and allowed a physician to choose one of the alternatives 
(Bouaud et al 1998, 2000). S´eroussi et al. used ONCODOC to evaluate usefulness of the 
system at two hospitals and found that ONCODOC helped increase the number of 
matched patients (S´eroussi et al. 1999, 2001)  
 Hammond and Sergot (1996) developed OaSiS, which has a graphical interface 
for entering patient data and extending the knowledge base. Papaconstantinou et al. 
(1998) developed a Bayesian system that selected clinical trials for cancer patients 
(Papaconstantinou et al., 1998, Theocharous et al. 1996). Their system learned 
conditional probabilities of medical test outcomes and evaluated the probability of a 
patient’s eligibility for each trial. Learning accurate probabilities requires sufficient 
medical records, but the available medical records were limited in volume. Moreover, the 
underlying Bayesian network needs to be modified when a new clinical trial is added.  
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 Fallowfield et al. investigated physicians’ cancer patient selection process for 
clinical trials, and compared manual and automatic selection (Fallowfield et al. 1997). 
Their study showed that expert systems could improve clinical trial patient selection 
accuracy. Carlson et al. (1995) conducted research on AIDS trials and showed that expert 
systems could improve patient selection. 
 In this section, I reviewed selected research on clinical trial and patient matching 
processes as well as decision support systems for clinical trial subject recruitment. Only a 
few attempts have so far been made on using NLP and text mining techniques. However, 
these studies only used basic level techniques or vaguely described the research process. 
In this essay, I propose a novel approach for the clinical trial and patient matching 
process using state-of-art NLP and text mining techniques.  
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4.3. Background 
Document Similarity Measurement 
 In the text mining and NLP fields, text similarity measurement plays an 
increasingly significant role. It measures the similarity between words, sentences, 
paragraphs, and documents. It is also an important component in tasks such as 
information retrieval, text classification, document clustering, topic detection, text 
summarization, word-sense disambiguation, automatic grading, and machine translation 
(Gomaa and Fahmy 2013). Over the past few decades, a large number of studies on 
measuring text and document similarity were conducted. Gomaa and Fahmy (2013) 
partitioned this issue into three approaches: string-based, corpus-based, and knowledge-
based.  
 There are two different types of similarity in words: lexical and semantic 
similarity. If two words have a similar character sequence, these two words are similar 
lexically. If two words have the same meaning or are used in the same context or the 
same way, they are similar semantically. String-based algorithms are used for lexical 
similarity, while corpus-based and knowledge-based algorithms are used for semantic 
similarity. 
 
String-Based Similarity Measures 
 A string metric measures similarity or dissimilarity (distance) between two text 
strings for string matching or comparison. Figure 14 shows 14 algorithms of string-based 
similarity measures; seven of them are character-based measures, while the other seven 
are term-based distance measures. 
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Figure 14. String-Based Similarity Measures (Gomaa and Fahmy 2013) 
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 The Longest Common SubString (LCS) algorithm is used to find the longest 
string (or strings) that is a substring (or are substrings) of two or more strings. The 
similarity between two strings is based on the length of contiguous chain of characters 
that exist in both strings. The longest common substring of the strings "ABABC", 
"BABCA", and "ABCBA" is string "ABC" of length 3. Other common substrings are 
"A", "AB", "B", "BA", "BC", and "C". Table 26 shows an output of the LCS algorithm. 
 
Table 26. Output of LCS algorithm 
  ABABC 
    ||| 
   BABCA 
    ||| 
    ABCBA 
 
 The problem definition for LCS can be described as follows.  
 Given two strings, S of length m and T of length n, find the longest strings that are 
substrings of both S and T. A generalization of this problem is the k-common substring 
problem. Given the set of strings S = {/0, … , /2} where |/| = 	5 and ∑5 = 6, find 
each 2	 ≤ 9	 ≤ :, the longest string that occurs as substrings of at least k strings. 
 Damerau-Levenshtein distance counts the minimum number of operations 
needed to transform one string into the other to measure the distance between two strings. 
An operation is defined as an insertion, deletion, or substitution of a single character, or a 
transposition of two adjacent characters. The Damerau–Levenshtein distance differs from 
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the classical Levenshtein distance by including transpositions among its allowable 
operations. The classical Levenshtein distance only allows insertion, deletion, and 
substitution operations. 
 The Damerau–Levenshtein distance between two strings a and b is given by 
;,(|<|, |=|) where:  
;,(>, ?) =
@AA
AAA
AB
AAA
AAA
C max(>, ?) 																																												>G min(>, ?) ? = 0,
K>5
@AA
BA
AC ;,(> − 1, ?) + 1;,(>, ? − 1) + 1;,(> − 1, ? − 1) +	1(;OPQ);,(> − 2, ? − 2) + 1 R
R			>G	>, ? > 1	<5	< = =T0	<5	<T0 = =
K>5
@AB
AC ;,(> − 1, ?) + 1;,(>, ? − 1) + 1;,(> − 1, ? − 1) + 1(;OPQ)R
R																																																						ℎVW>XV
 
 
 Jaro and Jaro–Winkler distance depend on the number and order of the common 
characters between two strings; it takes into account typical spelling deviations. Jaro is 
primarily used in the area of record linkage. Jaro–Winkler is an extension of Jaro 
distance, and it uses a prefix scale, which gives more favorable ratings to strings that 
match from the beginning for a set prefix length. The higher the Jaro–Winkler distance 
for two strings is, the more similar the strings are. The Jaro–Winkler distance metric is 
designed for short strings, such as person names. The score is normalized such that 0 
equates to no similarity and 1 is an exact match. 
 Problem definition for Jaro distance and Jaro–Winkler distance can be described 
as follows. 
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 The Jaro distance  of two given strings X0 and X( is 
 = Y 0, 	>G	K = 	013 [ K|X0| + K|X(| + K − K \ , 	ℎVW>XV, 
where m is the number of matching characters and t is the number of transpositions. 
 Jaro–Winkler distance uses a prefix scale p, which gives a more generous score to 
strings that match from the beginning for a set prefix length l. Given two strings s0 and s(, their Jaro–Winkler distance d] is: 
] =	 + (^1 − 
) 
Where  is the Jaro distance for strings X0 and X(. l is the length of common prefix at the 
start of the string up to a maximum of four characters. p is a constant scaling factor for 
how much the score is adjusted upwards because having common prefixes p should not 
exceed 0.25, otherwise the distance can become larger than 1. The standard value for this 
constant in Winkler's work is p = 0.1 
 The Needleman-Wunsch algorithm is an example of dynamic programming and 
is used in bioinformatics to align protein or nucleotide sequences. It performs a global 
alignment to find the best alignment over the entire of two sequences. The algorithm 
basically divides the full sequence into a series of smaller problems and uses the solutions 
for the smaller problems to reconstruct a solution to the larger problem. The Needleman–
Wunsch algorithm is widely used for optimal global alignment, when the two sequences 
are of similar length and the global alignment is important. 
 The Smith-Waterman algorithm is another example of dynamic programming 
and performs local sequence alignment. It performs a local alignment to find the best 
alignment between two strings or nucleotide or protein sequences. It is useful for 
101 
 
 
dissimilar sequences that are suspected of containing regions of similarity or similar 
sequence motifs within their larger sequence context. The distinction of the Needleman–
Wunsch algorithm is that negative scoring matrix cells are set to zero, which renders the 
local alignments visible. 
 Problem definition for Smith-Waterman algorithm can be described as follows. 
_(>, 0) = 0, 0 ≤ >	 ≤ K 
_(0, ?) = 0, 0 ≤ ?	 ≤ 5 
_(>, ?) = K<`
@AA
BA
AC 0_(> − 1, ? − 1) + X(<, =)			a<bℎ/a>XK<bℎ,K<`d0{_(> − 9, ?) +	e		$VV>5K<`fd0{_(>, ? − ) +	ef		#5XVW>5
, 1 ≤ > ≤ K, 1 ≤ ? ≤ 5 
Where a, b = String over the Alphabet ∑, m = length(a), n = length(b), s(a, b) is a 
similarity function on the alphabet, H(i, j) is the maximum similarity score between a 
suffix of a[1…i] and a suffix of b[1…j], eis the gap scoring scheme. 
 An n-gram is a sub-sequence of n items from a given sequence of text. The n-
gram similarity algorithm compares the n-gram characters or words in two strings. Text 
distance is calculated by dividing the number of same n-grams with maximal number of 
n-grams. 
 Block Distance is also known as rectilinear distance, boxcar distance, absolute 
value distance, g0 distance, city block distance, and Manhattan distance. It computes the 
distance that would be traveled to get from one data point to the other if a grid-like path is 
followed. The block distance between two items is the sum of the differences of their 
corresponding components. The block distance, 0, between two vectors p, q in an n-
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dimensional real vector space with fixed Cartesian coordinate system, is the sum of the 
lengths of the projections of the line segment between the points onto the coordinate 
axes. 
 Problem definition for block distance can be described as follows. 
0(^, h) = ‖^ − h‖0 =	i|^ − h|jk0  
Where (^, h) are vectors 
^ = (^0, ^(, … , ^j)	<5	h = (h0, h(, … , hj) 
 Cosine similarity is a measure of similarity between two vectors of an inner 
product space that measures the cosine of the angle between them. The cosine of 0° is 1, 
and it is less than 1 for any other angle. Thus, it determines an orientation and not 
magnitude: two vectors with the same orientation have a cosine similarity of 1; two 
vectors at 90° have a similarity of 0; and two vectors diametrically opposed have a 
similarity of -1, regardless of their magnitude. Cosine similarity is generally used in 
positive space, so the outcome is bounded within 0 and 1. One of the reasons for the 
popularity of cosine similarity is that it is very efficient to evaluate.  
 Cosine similarity can be derived by using the Euclidean dot product formula. 
< ∙ =	 = ‖<‖‖=‖ cos(m) 
Given two vectors of attributes, A and B, the cosine similarity, cos(θ), is represented 
using a dot product and magnitude as 
X>K><W>n = cos(m) = o ∙ p‖o‖‖p‖ = 	 ∑ o × pjk0q∑ (o)(jk0 ×q∑ (p)(jk0  
 Dice’s coefficient is defined as twice the number of common terms in the 
compared strings divided by the total number of terms in both strings. Dice’s coefficient 
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retains sensitivity in more heterogeneous data sets and gives less weight to outliers. 
Recently it has become popular in computer lexicography for measuring the lexical 
association score of two given words. 
 Definition of Dice’s coefficient can be described as follows. 
/r =	 2|o ∙ p||o|( +	|p|( 
where (o, p) are binary vectors 
o = (<0, <(, … , <j)	<5	p = (=0, =(, … , =j) 
 Euclidean distance or L2 distance is the "ordinary" distance between two points 
in Euclidean space and can be described as the square root of the sum of squared 
differences between corresponding elements of the two vectors. It can be described as 
follows. 
(^, h) = (h, ^) = 	q(h0 − ^0)( +	(h( − ^()( +	∙∙∙ 	+	(hj − ^j)( =	si(h − ^)(jk0  
where p and q are Euclidean vectors. 
 
 Jaccard similarity, also known as the Jaccard index, is used for comparing the 
similarity and diversity of sample sets. It is computed as the number of shared terms over 
the number of all unique terms in both strings. It can be described as follows. 
t(o, p) = 	 |o ∩ p||o ∪ p| 
Where 	0 ≤ J(o, p) ≤ 5 and if A and B are both empty, we define J(A,B) = 1. 
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 Matching coefficient, also known as Simple Matching Coefficient (SMC), is a 
vector-based approach that simply counts the number of similar terms or dimensions, on 
which both vectors are non-zero. Given two objects, A and B, each with n binary 
attributes, SMC is defined as follows. 
/ax	 = 	6yK=VW	G	a<bℎ>5	oW>=yVX6yK=VW	G	oW>=yVX = 	 azz +	a00azz +az0 +a0z +a00 
 
 Overlap coefficient, also known as Szymkiewicz-Simpson coefficient, is similar 
to the Jaccard index but considers two strings a full match if one is a subset of the other. 
It is defined as the size of the intersection divided by the smaller of the size of the two 
sets. Overlap coefficient is defined as follows. 
{VW<^(|, }) = 	 || ∩ }|min	(|||, |}|) 
 
Corpus-Based Similarity Measures 
 Corpus-based similarity is a semantic similarity measure that determines the 
similarity between words according to information gained from large corpora. A corpus, 
which is a large collection of written or spoken text data, is required to compute corpus-
based similarity. Figure 15 shows the algorithms for corpus-based similarity measures. 
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Figure 15. Corpus-Based Similarity Measures (Gomaa and Fahmy 2013) 
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 Hyperspace Analogue to Language (HAL) creates a semantic space from word 
co-occurrences. The basic premise that HAL relies on is that words with similar meaning 
repeatedly occur closely (i.e., co-occurrence). For example, in a large corpus of text, one 
could expect to see the words mountain, valley, and river appear close to each other 
often. The same might be true for mouse, cat, and dog. HAL creates an N by N matrix, 
where N is the number of words in its lexicon and each matrix element is the strength of 
association between the word represented by the column and row. As the text is analyzed, 
a focus word is placed at the beginning of a 10-word reading frame that records which 
neighboring words are counted as co-occurring, and the 10-word reading moves 
incrementally through a corpus of text. Matrix values are accumulated by weighting the 
co-occurrence inversely proportional to the distance from the focus word; closer 
neighboring words are thought to reflect more of the focus word's semantics and so are 
weighted higher. The semantic similarity between two words is given by the cosine of the 
angle between their vectors. 
 Latent Semantic Analysis (LSA) is one of the most popular techniques of the 
corpus-based similarity measure algorithm. It assumes that words are semantically 
similar if they appear together in the same context. In LSA, a T × D matrix is constructed 
from a text corpus where T is the number of terms in the corpus and D is the number of 
documents. With a T × D matrix, a singular value decomposition (SVD) is used to reduce 
the number of columns while preserving the similarity structure among rows. Words are 
then compared by taking the cosine of the angle between the two vectors formed by any 
two rows. 
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 Generalized Latent Semantic Analysis (GLSA) is a framework for computing 
semantically motivated term and document vectors. GLSA extends the applicability of 
the idea of the LSA approach, but GLSA focuses on term vectors instead of the dual 
document-term representation. GLSA requires a measure of semantic association 
between terms and a method of dimensionality reduction. The GLSA approach can 
combine any kind of similarity measure on the space of terms with any suitable method 
of dimensionality reduction. The traditional term document matrix is used in the last step 
to provide the weights in the linear combination of term vectors. 
 Explicit Semantic Analysis (ESA) is a vectorial representation of text that uses a 
document corpus as a knowledge-based measure. It computes the “semantic relatedness” 
between two arbitrary texts. The Wikipedia-based technique represents terms (or texts) as 
high-dimensional vectors; each vector entry presents the TF-IDF weight between the 
term and one Wikipedia article. The semantic relatedness between two terms (or texts) is 
expressed by the cosine measure between the corresponding vectors. The name "explicit 
semantic analysis" contrasts with latent semantic analysis (LSA) because the use of a 
knowledge base makes it possible to assign human-readable labels to the concepts that 
make up the vector space. 
 Cross-Language Explicit Semantic Analysis (CL-ESA) is a multilingual 
generalization of ESA. CL-ESA utilizes a document-aligned multilingual reference 
collection like Wikipedia to represent a document as a language-independent concept 
vector. The relatedness of two documents in different languages is assessed by the cosine 
similarity between the corresponding vector representations. 
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 Pointwise Mutual Information - Information Retrieval (PMI-IR) is a measure of 
the similarity of pairs of words. It uses a web-based search engine to calculate 
probabilities. The more often two words co-occur near each other on a web page, the 
higher is their PMI-IR similarity score. PMI-IR uses Pointwise Mutual Information (PMI) 
as follows. 
^K>(|, }) = 	 ^(`, n)p(x)p(y) =  ^(`|n)^(`) =  ^(n|`)^(n)  
 
 Second-order Co-occurrence Pointwise Mutual Information (SCO-PMI) is a 
semantic similarity measure using pointwise mutual information to sort lists of important 
neighbor words of the two target words from a large corpus. SOC-PMI can calculate the 
similarity between two words that do not co-occur frequently because they co-occur with 
the same neighboring words. The method considers the words that are common in both 
lists and aggregates their PMI values (from the opposite list) to calculate the relative 
semantic similarity. 
 Normalized Google Distance (NGD) is a semantic similarity measure based on 
the number of hits from the Google search engine for a given set of keywords. Keywords 
with the same or similar meanings tend to be "close" in units of Google distance, while 
words with dissimilar meanings tend to be farther apart. 
The Normalized Google Distance between two search terms x and y is as follows: 
6$(`, n) = 	max	{log G(`), log G(n)| − log G(`, n)logM −min	{log	G(`), log G(n)}  
where M is the total number of web pages searched by Google; f(x) and f(y) are the 
number of hits for search terms x and y; and f(x, y) is the number of web pages on which 
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both x and y occur. If the two search terms x and y never occur together on the same web 
page and they occur on separate web pages, the NGD is infinite. If they always occur on 
the same page, their NGD is zero. 
 Extracting Distributionally-related Words Using Co-occurrences (DISCO) is a 
Java-based application that allows the retrieval of the distributional similarity between 
arbitrary words and phrases. The Distributional Hypothesis in linguistics is derived from 
the semantic theory of language usage. The words that are used and occur in the same 
contexts tend to purport similar meanings. Large text collections are statistically analyzed 
to get the distributional similarity. When two words are subjected for exact similarity, 
DISCO simply retrieves their word vectors from the indexed data and computes the 
similarity according to Lin measure. If the most distributionally similar word is required, 
DISCO returns the second order word vector for the given word. DISCO has two main 
similarity measures: DISCO1 and DISCO2. DISCO1 computes the first order similarity 
between two input words based on their collocation sets. DISCO2 computes the second 
order similarity between two input words based on their sets of distributionally similar 
words. 
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Knowledge-Based Similarity Measures 
 Knowledge-based similarity is a semantic similarity measure that determines the 
degree of similarity between words using information derived from semantic networks. 
WordNet is the most popular semantic network in the area of measuring the knowledge-
based similarity between words. WordNet is a huge lexical database of English words. It 
groups English words into sets of synonyms called synsets, provides short definitions and 
usage examples, and records a number of relations among these synonym sets or their 
members. Synsets are interlinked by means of conceptual-semantic and lexical relations. 
Figure 16 shows knowledge-based similarity measures, which can be categorized into 
two groups: measures of semantic similarity and measures of semantic relatedness. 
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Figure 16. Knowledge-Based Similarity Measures (Gomaa and Fahmy 2013) 
 
 Measures of semantic similarity are often based on information regarding “is-a” 
relations found in a concept hierarchy. It takes two concepts as input and returns a 
numeric score that measures how much they are alike, based on is-a relationships. For 
example, common cold and illness are similar in that a common cold is a kind of illness. 
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However, there are other relations between concepts such as has-part, is-a-kind-of, is-a-
specific-example-of, and is-the-opposite-of that existing measures of similarity cannot 
use since they only account for is-a relations (Pedersen, 2005). This suggests that more 
general measures of semantic relatedness are needed to take advantage of the increasingly 
rich ontologies (particularly in the medical domain) that have a wealth of relations 
beyond is-a (Pedersen, 2005). 
 There are six measures of semantic similarity; three of them are based on 
information content and the other three measures use path length. 
 The res is a Perl module for computing semantic relatedness of word senses that 
uses an information content-based measure described by Resnik (1995). The res measure 
uses the information content of concepts, computed from their frequency of occurrence in 
a large corpus, to determine the semantic relatedness of word senses. 
 The lin (Lin 1998) and jcn (Jiang and Conrath 1997) measure and augment the 
information content of the Least Common Subsumer (LCS) with the sum of the 
information content of concepts A and B themselves. The lin measure scales the 
information content of the LCS by this sum, while jcn takes the difference of this sum 
and the information content of the LCS. 
 Three similarity measures are based on path lengths between concepts: lch 
(Leacock & Chodorow 1998), wup (Wu & Palmer 1994), and path. The lch measure 
finds the shortest path between two concepts and scales that value by the maximum path 
length in the “is-a” hierarchy in which they occur. The wup measure finds the path length 
to the root node from the LCS of the two concepts, which is the most specific concept 
they share as an ancestor. This value is scaled by the sum of the path lengths from the 
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individual concepts to the root. The measure path is equal to the inverse of the shortest 
path length between two concepts. 
 Furthermore, there are three measures of semantic relatedness. The hso by Hirst 
and St-Onge (1998), the lesk by Lesk (1986), and the vector. The hso measure works by 
finding lexical chains linking two word senses. There are three classes of relations that 
are considered: extra-strong, strong, and medium-strong. The maximum relatedness score 
is 16. The lesk measure works by finding overlaps in the terms of the two synsets. The 
relatedness score is the sum of the squares of the overlap lengths. The vector measure 
creates a co–occurrence matrix for each word used in the WordNet glosses from a given 
corpus and then represents each gloss and concept. 
 In this section, similarity measurement algorithms were reviewed and categorized 
according to three approaches: string-based measures, corpus-based measures, and 
knowledge-based measures. Generally, patient records and clinical trial subject eligibility 
criteria are not written in grammatically perfect sentences. In most cases, they are written 
as fragmented sentences or bullet points. Therefore, using corpus-based similarity 
measures is not a good idea since this requires a corpus, which is a large collection of 
written or spoken text data. Clinical trial subject eligibility criteria include a large number 
of medical terms, so cosine similarity from term-based distance measures was selected 
for the matching process. Also, knowledge-based measures were combined with term-
based distance measures by using UMLS semantic networks for semantic feature 
expansion. In this essay, I adopt a hybrid similarity measure, which combine term-based 
and knowledge-based distance measures. 
  
114 
 
 
4.4. Research Method 
 Figure 17 shows the steps for matching patient health records with clinical trial 
clusters and individual clinical trials. The first step of this research was to prepare clinical 
trial data from ClinicalTrials.gov and patient data from a prior research database. The 
second step was pre-processing using lemmatization, tokenization, and stop word 
removal. The next step was expanding the feature set with the custom dictionary and 
UMLS semantic network. A two-phase matching process was then conducted. Phase I 
matched patient information with the clusters that were generated in essay 2. Phase II 
matched patient information and clinical trials within the clusters. Also, patient 
information was matched with the entire clinical trial data set. Finally, internal and 
external evaluations were conducted. 
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Figure 17. Steps in Automatic Matching of Patient Record and  
Clinical Trial Clusters / Individual Clinical Trials 
 
4.4.1. Data Set 
 The patient data were acquired from a large community hospital in a major urban 
area in the Midwest, where, on average, 150 patients are diagnosed with breast cancer 
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each year. The original data set was collected for a prior research study (Gaudioso 2010) 
and has structured data such as demographic information as well as unstructured data 
such as documents (e.g., pathology, radiology, surgery reports). I collected only 
unstructured patient text data such as provider notes, biopsy reports, diagnostic workups, 
personal medical histories, physical exam reports, and surgery reports. All the patient 
data were de-identified, so the names of the patients were not included. I collected text 
data for a total of 148 patients, out of which data for 38 patients was excluded because 
there was not sufficient text data for those patients. Therefore, a data set of 110 patients 
was used for the matching process. 
 The database entities in the original study were normalized to secure data 
consistency. For the uniqueness of patient level records, the lower level data set was 
integrated into the higher level. The hierarchy of the patient data structure is presented in 
Figure 18. The lowest level of patient data is “encounter,” which is defined as “An 
interaction between a patient and healthcare provider(s) for the purpose of providing 
healthcare service(s) or assessing the health status of a patient” by ANSI-accredited 
standards developing organization, Health Level Seven International (HL7). The 
encounter level records were aggregated to Episode, which is defined as "An important 
event or series of events taking place in the course of continuous events” by Farlex 
Partner Medical Dictionary (2012). The episode level data was consolidated into case 
level. The definition of “case” in the medical field is “An instance of disease with its 
attendant circumstances,” according to the Farlex Partner Medical Dictionary (2012). 
Finally, all the case records were integrated into the patient level. 
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Figure 18. Hierarchy of Patient Data Structure 
 
 Figure 19 presents an SQL query statement to integrate a patient record, and 
Table 27 shows a sample of an integrated patient record. 
 
Figure 19. SQL Query Statement to Integrate Unique Patient Record 
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Table 27. Sample of Integrated Patient Record 
Patient ID Original Patient Record 
1000001 
Right breast, partial/simple mastectomy:  - Breast tissue with 
proliferative fibrocystic changes.  - Residual areas of lobular 
cancerization - No definite residual DCIS - Previous biopsy site 
changes.  - Margins free of involvement.  -Prognostic factors 
performed on previous biopsy    CS08-12007: ER +(97%), PR+(85%) 
PREOPERATIVE DIAGNOSIS:  Ductal carcinoma in situ, right 
breast, status post core biopsy, intermediate grade, cribriform type 
ER-PR positive. POSTOPERATIVE DIAGNOSIS:  Ductal carcinoma 
in situ, right breast, status post core biopsy, intermediate grade, 
cribriform type ER-PR positive. PROCEDURE:  Right mastectomy 
with level I axillary node excision. 1.  This is a 50-year-old woman, 
who has had right mastectomy for recently diagnosed ductal 
carcinoma in situ of the right breast that also has features of lobular 
cancerization.  She is stage pT1N0M0 and I recommend hormonal 
therapy with tamoxifen 20 mg daily for 5 
 
 Clinical trial data were collected from ClinicalTrials.gov. The search term "breast 
cancer" was applied to limit clinical trials to only the breast cancer domain. A total of 
1,660 breast cancer clinical trials from January 1, 2010, to January 1, 2012, were 
downloaded as a collection of XML format files. A custom parser was used for removing 
unnecessary tags, and the clinical trial subject eligibility section was divided based on 
two opposite criteria: Inclusion and Exclusion. The basic structured information for 
eligibility criteria, gender, and age range was also maintained by including that 
information in the data file naming rule. 
 The clinical trial cluster data came from the second essay. I generated 596 clusters 
that had more than single instance and labeled each cluster using the most frequent 
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synonym chunk of semantic features. The same cluster data and labels were used for the 
matching process in this essay. 
 
4.4.2. Pre-processing 
 Tokenization and lemmatization were performed for the patient data set with 
Stanford CoreNLP. The second step in pre-processing was stop word removal. Fox’s stop 
words list with the Apache Lucene framework was applied to sieve out all insignificant 
words in the data. Table 28 presents a sample of the pre-processed patient record. 
 
Table 28. Sample of Pre-processed Patient Record 
Patient ID Pre-processed Patient Text Data 
1000001 
right breast partial simple mastectomy breast tissue proliferative 
fibrocystic change residual area lobular cancerization definite residual 
dci previous biopsy site change margin free involvement prognostic 
factor perform previous biopsy cs08-12007 er 97 pr 85 preoperative 
diagnosis ductal carcinoma situ right breast status post core biopsy 
intermediate grade cribriform type er pr positive postoperative 
diagnosis ductal carcinoma situ right breast status post core biopsy 
intermediate grade cribriform type er pr positive procedure Right 
mastectomy level axillary node excision 1 50-year old woman right 
mastectomy recently diagnose ductal carcinoma situ right breast 
feature lobular cancerization stage pt1n0m0 recommend hormonal 
therapy tamoxifen 20 mg daily 5 
 
4.4.3. Matching with a Custom Dictionary 
 First, all trigram combinations from the pre-processed data set were identified; 
then each trigram term was matched with the custom dictionary. The three unigram 
tokens in the matched trigram were eliminated from the original data set. After all trigram 
120 
 
 
matching was completed, all bigram combinations from the modified data set were 
derived and matched with the custom dictionary. Table 29 shows trigram matching 
results between patient record 1000013 and the custom dictionary. 
Table 29. Trigram Matching with the Custom Dictionary 
Patient ID Pre-processed patient record 
Trigram Matching with  
The Custom Dictionary 
1000013 
successful ultrasound guided core 
biopsy highly suspicious palpable 
mass 12 30 position right breast ribbon 
shaped clip placement pathology grade 
iii invasive ductal carcinoma 
concordant 2 successful ultrasound 
guided vacuum assisted biopsy right 
breast 9 00 position s shaped clip 
placement pathology grade iii invasive 
ductal carcinoma concordant 3 Post 
biopsy digital right mammogram show 
accurate placement biopsy marking 
clip separate distance 6.4 cm.yes 
hematoma 
1000013200001430000075000042 1 
successful ultrasound guided core 
biopsy highly suspicious palpable 
mass 12 30 position right breast ribbon 
shaped clip placement pathology grade 
iii invasive ductal carcinoma 
concordant 2 successful ultrasound 
guided vacuum assisted biopsy right 
breast 9 00 position s shaped clip 
placement pathology grade iii invasive 
ductal carcinoma 
invasive_ductal_carcinoma 
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 Table 30 shows bigram matching results between patient record 1000013 and the 
custom dictionary. 
Table 30. Bigram Matching with the Custom Dictionary 
Patient ID Pre-processed patient record 
Bigram Matching with  
The Custom Dictionary 
1000013 
successful ultrasound guided core 
biopsy highly suspicious palpable 
mass 12 30 position right breast ribbon 
shaped clip placement pathology grade 
iii invasive ductal carcinoma 
concordant 2 successful ultrasound 
guided vacuum assisted biopsy right 
breast 9 00 position s shaped clip 
placement pathology grade iii invasive 
ductal carcinoma concordant 3 Post 
biopsy digital right mammogram show 
accurate placement biopsy marking 
clip separate distance 6.4 cm.yes 
hematoma 
1000013200001430000075000042 1 
successful ultrasound guided core 
biopsy highly suspicious palpable mass 
12 30 position right breast ribbon 
shaped clip placement pathology grade 
iii invasive ductal carcinoma 
concordant 2 successful ultrasound 
guided vacuum assisted biopsy right 
breast 9 00 position s shaped clip 
placement pathology grade iii invasive 
ductal carcinoma 
core_biopsy 
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4.4.4. Matching with the UMLS Semantic Network 
 A patient record is not a wordy document but is a succinct depiction of patient 
status. Moreover, the contents in a patient record are written by a healthcare provider and 
the target audience includes healthcare experts, so the patient record usually includes 
numerous medical terms. For that reason, I expanded the feature set in the patient record 
and the clinical trial eligibility section with synonymously related terms from the UMLS 
Semantic Network, based on semantic relatedness. 
 All bigram and trigram terms that matched with the custom dictionary were 
processed with the UMLS Semantic Network to find synonyms. Each bigram and trigram 
term was queried with the UMLS Semantic Network using a custom query statement.  
 Table 31 shows the UMLS synonym matching results for each trigram and bigram 
term. 
Table 31. UMLS Synonym Matching Results for Trigram and Bigram 
Patient ID 
Trigrams and Bigram Found 
in Custom Dictionary 
UMLS Synonym Matching 
1000013 
invasive_ductal_carcinoma 
 
core_biopsy 
 
 
No Match 
 
Biopsy-action 
BX-Biopsy 
Biopsy_sampling 
 
4.4.5. Matching patient records with clinical trials within a cluster  
 There is considerable evidence that information technology could improve the 
subject recruitment process in clinical research.  Dugas et al. (2009) showed that 
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complete, high-quality, and accurate data can significantly enhance the recruitment 
process. However, most relevant patient information still remains in an unstructured 
format (e.g., clinical notes, clinical assessments). The main objective in this essay is to 
find the best matching trials for a patient and to do this efficiently. Thus, the process 
starts with matching the patient record with clinical trial information  
 In this study I selected cosine similarity to compute the matching score between a 
patient record and a clinical trial cluster as well as between the patient record and each 
clinical trial, because cosine similarity is a measure of similarity between two vectors and 
is most commonly used in high-dimensional positive spaces. One of the reasons for the 
popularity of cosine similarity is that it is very efficient to evaluate, especially for sparse 
vectors, as only the non-zero dimensions need to be considered. 
 The cluster matching process was a two-step process. First, the matching between 
patient records and clinical trial clusters was conducted, and then each trial within the 
best matching cluster was also compared with the patient record. In the cluster matching, 
I included all clusters, including clusters with one trial. One of the main objectives in 
clustering is to reduce the search space for patient and trial matching. Therefore, to 
validate the efficiency of clustering, I compared the trial matching results within clusters 
with the matching results for the entire trial data set. Also, I set the threshold value for the 
best matched cluster as 0.95. All clusters that scored at or above 0.95 were included for 
the cluster matching. 
 Sample results for cluster matching are presented in Table 32. The highest 
matching score between patient and cluster is 1 and the lowest score is 0.4666. After all 
the best matching clusters for each patient were identified, I compared the patient records 
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with the clinical trials within those clusters. Phase I matches the patient records with the 
cluster information, while Phase II matches patient records with clinical trials within the 
matched clusters. In Phase II matching, two experiments were also conducted.  In the first 
experiment in Phase II, the matching process was stopped when it found a trial whose 
similarity score was more or equal to 0.90. In the second experiment, I compared the 
patient record with all the trials in the best matching clusters. I also examined the 
matching results with the entire trial data set for the purpose of comparison. Figure 20 
presents the matching experiments conducted in this study. 
 
 
Figure 20. Matching Experiments in Research 
 
 In each trial, the subject eligibility criteria were divided into two groups: 
“Inclusion” and “Exclusion.” Inclusion criteria are characteristics that the prospective 
subjects must have if they are to be included in the study, while exclusion criteria are 
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those characteristics that disqualify prospective subjects from inclusion in the study. 
Therefore, in this experiment, I excluded the trials whose exclusion criteria matched with 
the patient record. For example, the exclusion criteria included terms like “smoking” or 
“pregnant” because the study participant should not smoke or should not be pregnant. If 
any feature from the exclusion criteria matched with any feature of the patient record, 
that match was not included in the final results. 
 Table 33 shows the results of the trial within cluster matching for a patient. The 
highest matching score between the patient and trial within the cluster is 0.8101 and the 
lowest is 0.4730. 
 
4.4.6. Matching patient record with entire clinical trial  
 Additional experiments were performed with each patient record and the entire set 
of clinical trials to find the best matches, regardless of clusters. Table 34 shows the 
sample results of matching between a patient and trials from the entire pool. The highest 
matching score between patient and trial information is 1 and the lowest matching is 
0.1708. 
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Table 32. Sample of Patient and Cluster Matching Result 
Patient 
ID 
Patient_text Cluster_ID Cluster_label 
Cluster 
matching 
score 
1000001 
Right breast, partial/simple mastectomy:  - Breast 
tissue with proliferative fibrocystic changes.  - 
Residual areas of lobular cancerization  - No 
definite residual DCIS  - Previous biopsy site 
changes.  - Margins free of involvement.  -
Prognostic factors performed on previous biopsy    
CS08-12007: ER +(97%), 
PR+(85%) ,PREOPERATIVE DIAGNOSIS:  
Ductal carcinoma in situ, right breast, status post 
core biopsy, intermediate grade, cribriform type 
ER-PR positive. POSTOPERATIVE DIAGNOSIS:  
Ductal carcinoma in situ, right breast, status post 
core biopsy, intermediate grade, cribriform type 
ER-PR positive. PROCEDURE:  Right mastectomy 
with level I axillary node excision. ,1.  This is a 50-
year-old woman, who has had right mastectomy for 
recently diagnosed ductal carcinoma in situ of the 
right breast that also has features of lobular 
cancerization.  She is stage pT1N0M0 and I 
recommend hormonal therapy with tamoxifen 20 
mg daily for 5  
Inc(24)_Exc(127) 
Carcinoma, no subtype|Epithelial tumor, 
malignant|Carcinoma|Malignant 
epithelial tumor|Malignant epithelial 
tumour|Epithelial tumour, 
malignant||Drug preparation|Drug 
product|Drug|Medicinal product|General 
drug type|Pharmaceutical / biologic 
product|Medicine|Medication|Drug, 
medicament or biological 
substance|Drug or medicament 
1 
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Table 33. Sample of Patient and Trial within Cluster Matching Result 
Patient 
ID 
Patient_text 
Best matching Trial within Cluster 
CT_ID CT_text 
CT 
matching 
score 
1000001 
Right breast, partial/simple 
mastectomy:  - Breast tissue with 
proliferative fibrocystic changes.  - 
Residual areas of lobular cancerization  
- No definite residual DCIS  - Previous 
biopsy site changes.  - Margins free of 
involvement.  -Prognostic factors 
performed on previous biopsy    CS08-
12007: ER +(97%), 
PR+(85%) ,PREOPERATIVE 
DIAGNOSIS:  Ductal carcinoma in 
situ, right breast, status post core 
biopsy, intermediate grade, cribriform 
type ER-PR positive. 
POSTOPERATIVE DIAGNOSIS:  
Ductal carcinoma in situ, right breast, 
status post core biopsy, intermediate 
grade, cribriform type ER-PR positive. 
PROCEDURE:  Right mastectomy 
with level I axillary node excision. ,1.  
NCT01183663 
Inclusion Criteria:            1. Patients with advanced or 
metastatic cancer that is refractory to standard therapy,              
has relapsed after standard therapy, or for which there is no 
standard therapy              available.            2. Patients must 
be >/= 3 weeks beyond treatment with a cytotoxic 
chemotherapy regimen,              therapeutic radiation, or 
major surgery. After targeted or biologic therapy there              
should be 5 half-lives or three weeks, whichever is shorter. 
Patients may have              received palliative localized 
radiation immediately before or during treatment,              
providing radiation is not delivered only to the site of 
disease being treated under              this protocol.            3. 
Eastern Cooperative Oncology Group (ECOG) performance 
status </= 2            4. Patients must have normal organ and 
marrow function, defined as absolute neutrophil              
count >/= 1,000/mL; platelets >/=50,000/mL (unless these 
abnormalities are due to              bone marrow involvement); 
creatinine clearance >/= 50 ml/min by Cockcroft-Gault              
formula; total bilirubin </= 2.0; and alanine 
aminotransferase (ALT)/ serum glutamic              pyruvic 
transaminase(SGPT) </= 5 X ULN (unless patient has liver 
metastases).            5. All study participants must be 
registered into the mandatory RevAssist® program, and              
0.6410 
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This is a 50-year-old woman, who has 
had right mastectomy for recently 
diagnosed ductal carcinoma in situ of 
the right breast that also has features of 
lobular cancerization.  She is stage 
pT1N0M0 and I recommend hormonal 
therapy with tamoxifen 20 mg daily for 
5  
be willing and able to comply with the requirements of 
RevAssist®.            6. Females of childbearing potential 
(FCBP) must have a negative serum or urine              
pregnancy test with a sensitivity of at least 50 mIU/mL 
within 10 - 14 days prior to              and again within 24 
hours of prescribing lenalidomide (prescriptions must be 
filled              within 7 days) and must either commit to 
continued abstinence from intercourse or              begin 
TWO acceptable methods of birth control, one highly 
effective method and one              additional effective 
method AT THE SAME TIME, at least 28 days before she 
starts              taking lenalidomide. FCBP must also agree to 
ongoing pregnancy testing. Men must              agree to use a 
latex condom during sexual contact with a FCBP even if 
they have had a              successful vasectomy.            7. 
Patients must be able to understand and be willing to sign a 
written informed consent              document.            8. Must 
be >/= 18 years of age.          Exclusion Criteria:            1. 
Any serious medical condition, laboratory abnormality, or 
psychiatric illness that              would prevent the subject 
from signing the informed consent form.            2. 
Uncontrolled intercurrent illness, including, but not limited 
to, uncontrolled              infection, uncontrolled asthma, 
need for hemodialysis, need for ventilatory support.            
3. Pregnant or breast feeding females. (Lactating females 
must agree not to breast feed              while taking 
lenalidomide).            4. Use of any other experimental drug 
or therapy within 21 days of baseline.            5. Known 
hypersensitivity to thalidomide.            6. History of 
hypersensitivity to any component of the formulation.            
7. The development of erythema nodosum, if characterized 
by a desquamating rash while              taking thalidomide or 
  
1
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similar drugs.            8. Patients unwilling or unable to sign 
informed consent document.            9. Uncontrolled 
systemic vascular hypertension (Systolic blood pressure 
>140 mmHg,              diastolic blood pressure > 90 mmHg 
on medication) for patients treated in the              
bevacizumab or sorafenib arms.           10. Patients with 
active deep venous thrombosis or pulmonary embolism or 
patients              receiving anti-coagulation.           11. 
Patients with clinically significant cardiovascular disease: 
History of              cerebro-vascular accident (CVA) within 6 
months; Myocardial infarction or unstable              angina 
within 6 months; Unstable angina pectoris.           12. 
Uncontrolled intercurrent illness, including, but not limited 
to, ongoing or active              infection requiring parenteral 
antibiotics on Day 1.           13. Major surgical procedure, 
open biopsy or significant traumatic injury within 28 days              
prior to Day 0 of protocol treatment.           14. Patients that 
are taking CYP3A4 inducers and/or inhibitors, being 
considered for the              temsirolimus arm: If a patient has 
a history of taking CYP3A4 inducers and/or              
inhibitors prior to enrollment on the temsirolimus arm, it is 
strongly recommended              that the patient stops the 
drug and waits at least 5 half-lives of said drug before              
initiating therapy on the temsirolimus arm. 
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Table 34. Sample of Patient and Trial among Entire Trial set Matching Result 
Patient 
ID 
Patient_text 
Best matching Trial among Entire Trial set 
CT_ID CT_text 
CT 
matching 
score 
1000001 
Right breast, partial/simple 
mastectomy:  - Breast tissue with 
proliferative fibrocystic changes.  - 
Residual areas of lobular cancerization  
- No definite residual DCIS  - Previous 
biopsy site changes.  - Margins free of 
involvement.  -Prognostic factors 
performed on previous biopsy    CS08-
12007: ER +(97%), 
PR+(85%) ,PREOPERATIVE 
DIAGNOSIS:  Ductal carcinoma in 
situ, right breast, status post core 
biopsy, intermediate grade, cribriform 
type ER-PR positive. 
POSTOPERATIVE DIAGNOSIS:  
Ductal carcinoma in situ, right breast, 
status post core biopsy, intermediate 
grade, cribriform type ER-PR positive. 
PROCEDURE:  Right mastectomy 
with level I axillary node excision. ,1.  
This is a 50-year-old woman, who has 
had right mastectomy for recently 
NCT01757730 
Inclusion Criteria:          Any participant 18 years or 
older and are MR safe.          Exclusion Criteria:          
That study participants will be excluded if they have 
any unapproved metal in their         bodies, and that 
the volunteers are  pregnant or possible of becoming 
pregnant. Also if         the participants are 
claustrophobic. 
0.9813 
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diagnosed ductal carcinoma in situ of 
the right breast that also has features of 
lobular cancerization.  She is stage 
pT1N0M0 and I recommend hormonal 
therapy with tamoxifen 20 mg daily for 
5  
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4.5. Results 
 When I included single-instance and two-instance clusters in the experiment, the 
best match score between patient and cluster was always 1. Also, all the patients matched 
with multiple best clusters with score 1, and the number of best matched clusters ranged 
from 2 to 128. Table 35 shows the score results for patient and cluster matching. All the 
patients had at least one best match with a cluster, and all of the best matches had a score 
of 1. Thus, the upper bound and lower bound scores were both 1. 
 
Table 35. Matching Results for Patient and Clinical Trial Clusters 
Highest Best Matching Score 1 
Lowest Best Matching Score 1 
Number of Multiple Matches 110 
Range of Multiple Matches 2 to 128 
 
 The match results between patient and individual clinical trials within the clusters 
were obtained through two different experiments. In the first experiment, the matching 
process was stopped when it found a trial whose match score was more than 0.90; the 
results from that experiment are presented in Table 36. 
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Table 36. Matching Results for Patient and Trial within Best Matched Cluster  
(Stop at First Match) 
Highest Best Matching Score 0.9862 
Lowest Best Matching Score 0. 9289 
Average Best Matching Score 0.9632 
 
 In the second experiment, I compared the patient record with all the trials in the 
best clusters. The results from the second approach are presented in Table 37. There are 
several trial studies that scored 1 because the description of eligibility criteria for those 
trials was extremely short. The cosine similarity measure only considers orientation, not 
magnitude, so very short documents could have raised the level of noise in the 
experiment. To address this shortcoming, all the matches that scored 1 were removed 
from the results. 
 
Table 37. Matching Results for Patient and Trial within Best Matched Cluster (All Trials) 
Highest Best Matching Score 0.9931 
Lowest Best Matching Score 0.9493 
Average Best Matching Score 0.9845 
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 The matching results between patient and the entire trial set are also presented in 
Table 38. This matching took around seven times longer than the one involving patient 
and all trials in the best clusters. Computationally, it incurred higher costs but produced 
similar results as those from patient and trial within the best matched cluster. Table 38 
shows the match results between patient and single clinical trial in the entire trial set. 
 
Table 38 Matching Results between Patient and Entire Trial 
Highest Best Matching Score 0.9931 
Lowest Best Matching Score 0.9493 
Average Best Matching Score 0.9845 
Number of Multiple Matches 22 
Range of Multiple Matches 2 
 
 The efficiency of the matching process was evaluated by measuring the matching 
algorithm computing time. The main objective of clustering trials in the second essay was 
to reduce the search space and lower the computational costs for finding the best trial for 
a patient. To evaluate the efficiency of the clustering approach, I investigated the 
computing time for the three matching experiments. The system specification for this 
research is presented in Table 39. 
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Table 39. Research System Specification 
OS Name 
Microsoft Windows Server 2008 R2 Standard,  
64 bit 
OS Version 6.1.7601 Service Pack 1 Build 7601 
Processor 
Intel(R) Xeon(R) CPU E5440 @ 2.83GHz, 2826 
Mhz, 1 Core(s), 1 Logical Processor(s) 
BIOS Version/Date 
American Megatrends Inc. 080002, 5/5/2008 
SMBIOS Version 2.3 
Total Physical Memory 12.0 GB 
Available Physical 
Memory 
9.12 GB 
Total Virtual Memory 24.0 GB 
Available Virtual 
Memory 
18.0 GB 
Page File Space 12.0 GB 
Disk Size 270.99 GB (290,977,505,280 bytes) 
Program Language java version "1.6.0_45" 
Integrated Development 
Environment 
Eclipse IDE for Java Developers 
Version: Juno Service Release 2 
Build id: 20130225-0426 
Database MySQL 5.5.30 
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 Table 40 shows the computing times for the matching process of patient and the 
first matched trial within the best matched cluster.  
 
Table 40 Computing Time for the Matching Process of Patient and  
Trial within Best Matched Clusters (Stop at First Match) 
Longest Computing Time 0.3397 sec 
Shortest Computing Time 0.0528 sec 
Average Computing Time 0.0867 sec 
 
 Table 41 shows the computing time for the matching process of patient and all 
trials within the best matched clusters.  
 
Table 41 Computing Time for the Matching Process of Patient and  
Trial within Best Matched Clusters (All trial) 
Longest Running Time 0.8298 sec 
Shortest Running Time 0.1246 sec 
Average Running Time 0.3356 sec 
 
 Table 42 shows the computing time for the matching process of patient and the 
entire trial set. 
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Table 42 Computing Time for the Matching Process of Patient and Entire Trial Set 
Longest Running Time 3.531461 sec 
Shortest Running Time 2.070947 sec 
Average Running Time 2.2516 sec 
 
 In order to analyze the differences among three group means and variation among 
and between groups, I conducted the analysis of variance (ANOVA) test. Table 43 shows 
a summary of the three experimental groups, and Table 44 presents the results of the 
ANOVA test. 
 
Table 43. Summary of Three Experiment Groups for Patient and Trial Matching 
Groups Counts Sum Average Variance 
Patient and Trial within  
Best Matched Clusters  
(Stop at First Match) 
110 9.6327 0.0867 0.0036 
Patient and Trial within  
Best Matched Clusters 
(All trials) 
110 37.5165 0.3379 0.0238 
Patient and Entire Trial Set 110 250.3816 2.2556 0.04488 
 
 Table 44 shows that the p-value is less than 0.05, indicating that the mean values 
of computing times for the three experimental groups were significantly different.   
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Table 44. Results of ANOVA Test for Three Experiment Groups 
Source of 
Variation 
SS df MS F p-value F crit 
Between 
Groups 
312.4595 2 156.2297 6477.9563 0.00 3.0230 
Within 
Groups 
7.95865 330 0.02411    
Total 320.4182 332     
 
 The mean differences among the three groups were statistically different, and it 
can be interpreted that the clustering approach in the patient and clinical trial matching 
can significantly expedite the clinical trial subject recruitment process. 
 A two-tail pairwise t-test was conducted to find differences among the groups. 
Table 45 shows results of pairwise t-test. All the p-values were less than 0.5, and 
statistically significant differences existed among the three groups. 
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Table 45. Results of Pairwise t-test (Two tail) 
Groups Pairwise t-test (two tail) 
Patient and Trial within  
Best Matched Clusters  
(Stop at First Match) 
0.0001 
Patient and Trial within  
Best Matched Clusters 
(All trials) 
0.0001 
Patient and Entire Trial Set 0.0001 
 
 The quality of the matching was evaluated in this study using psycholinguistic 
evaluation. This evaluation approach is usually used for assessing the quality of semantic 
similarity measures. The psycholinguistic approach compares the computational 
approaches with human judgements. The correlation between the computational approach 
and human assessment is used as an evaluation measure to judge the quality of the 
similarity measure. The matching results were evaluated internally by researchers 
involved in the study and were then reviewed by an external medical expert who was a 
medical doctor as well as a PhD in management science. The internal researchers 
preliminarily tested the quality of the matching results and then the external medical 
expert assessed the quality of a sample of five final matching results. Table 46 shows the 
results of expert evaluation. The expert review reported one ‘Very Good’ and four 
‘Average’ ratings. The expert provided comments as part of the evaluation. The 
comments on average ratings explained why he didn’t mark those matches ‘Very Good’ 
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or ‘Good’. All the ‘Average’ rated matches were because of significant missing 
information in patient data that is required for a good match. For example, one of the 
expert’s comments was that “Match on Confirmed diagnosis and ER, PR, Her status, and 
ax LNs. However, we are missing data on menopausal status and performance status…” 
 The results from three experiments were discussed and showed the proposed two 
step matching results provided statistically improved performance. The matching results 
could be used for patient recruitment, estimation of clinical trial feasibility, and helping 
terminal disease patients. 
 
Table 46. Results of Expert Evaluation for 5 Sample Matches 
Value in Likert Scale Count 
Very Good 1 
Good - 
Average 4 
Poor - 
Very Poor - 
Total 5 
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4.6. Discussion 
 To the best of our knowledge, no attempt has so far been made to build an entire 
automatic matching process for clinical trial and patient information using state-of-the-art 
NLP and text mining algorithms. Also, this research is the first study that adopts the 
semantic-based feature expansion technique, which can improve clinical trial text 
analysis performance. Based on prior studies, the n-gram feature induction approach 
yielded more accurate outcomes for machine learning-based text analysis. I tried to 
capture the n-gram medical terms using the domain-specific custom dictionary, which, in 
clinical trial research, is the first attempt at applying the n-gram feature induction 
approach. Previous research on clinical trials failed to grasp the characteristics of the two 
opposite criteria in the eligibility section. In this research, we divided the subject 
eligibility section into “Inclusion Criteria” and “Exclusion Criteria” section to reflect the 
impact of each set of criteria precisely. Finally, we matched patient data with clinical trial 
clusters, under which similar alternative clinical trials were grouped. The results of the 
matching reduced healthcare practitioners’ search space for clinical trials and 
significantly enhanced their patients’ participation opportunity in trials.  
 I have presented a feasibility study for an NLP and text mining-based approach to 
matching patient records with clinical trials. Using a real-world patient data set, we 
described various framework and algorithms to address issues in the automatic patient 
recruitment process. 
 This study contributes to both research and practice. The study contributes to 
research by proposing a framework and providing algorithms based on semantic feature 
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expansion. Moreover, the algorithms and framework from this research could be used for 
different types of diseases and patient groups. 
 This study is not without limitations. In its current scope, it has limited 
generalizability. I only focused on the breast cancer domain with a limited set of patient 
records. Furthermore, this study adopted the cosine similarity measure in the matching 
process. However, there are several similarity measures that have been used in other 
research domains, such as information retrieval and computer science. Emerging 
similarity measure algorithms could be evaluated in the future. Moreover, by the nature 
of cosine similarity, semantics of documents were not considered in this research. 
Negation expression in clinical trial and patient text could not be captured. 
 There are several ways in which future research could strengthen the results of 
this study. As a further extension of our work, future researchers could conduct a field 
study involving a real hospital environment. Future studies could investigate the proposed 
model in the context of different types of disease. Semantic analysis could also be 
included in future research. 
 About 85% of people with cancer were either unaware or unsure that participation 
in clinical trials was an option, although about 75% of them said they would have been 
willing to enroll had they known it was possible. However, the clinical trial subject 
matching process is labor intensive and error prone. Our research would streamline the 
entire matching process and provide effective support to terminal disease patients. 
  
143 
 
 
CHAPTER 5 
Conclusion and Future Directions 
 
 
“It is a very sad thing that nowadays there is so little useless information.” 
Oscar Wilde 
 
5.1. Introduction 
 It has been extensively recognized that recruitment of an adequate number of 
participants is essential for success of a clinical trial. Several studies have found that low 
participation in clinical trials is a significant issue resulting in inadequate statistical 
analyses of outcomes, premature closure of trials, longer trial duration, and higher costs 
of medical treatment. 
 In the field of oncology, fewer than 3% of potentially eligible patients enroll in 
clinical trials, and patient enrollment for clinical trials is as low as 2% of patient 
recruitment goals. Furthermore, more than 75% of participants are not even aware that 
trials exist, even though surveys have shown that a majority of people would be open to 
participating in these studies if they knew about them. 
 Extensive literature has been written about barriers to clinical trial participation, 
and one of the salient barriers for potential participation is participation of physicians. 
The participation of physicians is necessary to the success of clinical trial subject 
recruitment because they serve a critical role in helping their patients access trials. 
However, they do not have enough time to identify eligible study subjects efficiently, or 
they simply forget to offer and enroll patients in possible trials. 
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 Therefore, it is necessary to develop new technologies and automatic tools that 
can process large text data into useful information and knowledge intelligently. NLP and 
text mining is a technique that can combine traditional data analysis methods with 
complex algorithms to deal with large amounts of text data. Additionally, text mining is a 
complex process that can extract the unknown and valuable modes or rules from mass 
data. 
 This three-essay dissertation attempts to contribute a solution to clinical trial 
subject recruitment problem. This study aims to provide an automatic matching 
framework for patient text information and clinical trial subject eligibility description. To 
achieve the main objective, I created a domain-specific custom dictionary as a lexical 
resource in essay 1, generated clinical trial clusters for the breast cancer domain in essay 
2, and proposed a two-step automatic matching process in essay3. 
 One of the most time-consuming and high labor cost tasks in text mining research 
is the creation, compilation, and customization of the necessary lexicons. The first essay 
attempted to build a domain-specific lexicon focusing on breast cancer and showed the 
semi-automated dictionary building process. The evaluations for the breast cancer 
domain-specific dictionary shows that even though the coverage of a domain-specific 
dictionary is slightly less than the UMLS Metahthesaurus, the efficiency is more than 30-
fold higher than UMLS resources 
 This second essay grouped and summarized clinical trial subject eligibility using 
the clustering approach. This essay also showed the framework for clustering clinical trial 
and labeling process. The findings from the second essay suggest that the clustering 
145 
 
 
approach could help practicing physicians reduce the search space of potential clinical 
trials. 
 The last essay proposed an entire automatic matching process for clinical trial and 
patient information using state-of-the-art NLP and text mining algorithms. This study 
contributes to both research and practice. The study contributes to research by providing 
algorithms and a framework based on semantic feature expansion. Moreover, the findings 
in this research, such as algorithms and the framework on which they are based, could be 
used for different types of diseases and patient groups. 
 
5.2. Limitations 
 No claim is made as to the completeness of this research study. For the first essay, 
the coverage rate of the custom dictionary is relatively low because the data set included 
not only noun but also verb, adverb, and adjective words. Second, the custom dictionary 
included limited online sources. Thus, if a more comprehensive resource is included in 
future research, it will result in better performance. 
 The second essay focused only on the context of the breast cancer domain, which 
may represent lack of generalizability. While agglomerative hierarchical clustering with 
cosine distance was adopted to cluster clinical trials, other clustering algorithms and 
distance measures need to be compared. 
 The scope of the last essay has limited generalizability. I focused only on the 
breast cancer domain with limited patient records. The last essay also adopts cosine 
similarity to measure in the matching process. However, there are several other similarity 
measures that can be used for other research domains, such as information retrieval and 
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computer science. Emerging similarity measure algorithms should be evaluated. 
Semantic analysis of documents were not considered in this research. Negation 
expressions in data were not captured. 
 
5.3. Future Directions 
 As described in the conclusion section for each individual essay, there is always 
room for enhancement and extension of the algorithms used in these essays. Future 
research for the first essay could be evaluation with only a noun word data set, which 
could increase the coverage rate of custom dictionary. The custom dictionary included 
limited online sources. Therefore, if a more comprehensive resource is included in future 
research, it will result in better performance.  
 There are several ways in which future research could strengthen the results of the 
second essay. First, future studies could investigate the proposed clustering framework in 
the context of different kinds of diseases to extend generalizability. Second, different 
approaches for clustering and document similarity metrics could be used. For example, 
Latent Dirichlet allocation (LDA), latent semantic indexing, independent component 
analysis, probabilistic latent semantic indexing, non-negative matrix factorization, and 
Gamma-Poisson distribution techniques are used in bioinformatics research. These new 
techniques could be applied in future research. 
 As a further extension of the third essay, researchers could conduct a field study 
involving a real hospital environment. Also, future studies could investigate the proposed 
model in the context of different types of diseases. To capture negation expressions, 
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semantic analysis could be included in future direction. Our research would streamline 
the entire matching process and provide effective support to terminal disease patients. 
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APPENDIX: 5 Sample Matching Results between Patient and Clinical Trials (Essay III) 
 
Patient 
ID 
Patient_text CT_text 
Matched 
Terms 
Expanded 
Matched 
Terms 
Matching 
evaluation 
Comments 
(Optional) 
1000001 
Right breast, partial/simple mastectomy:  - 
Breast tissue with proliferative fibrocystic 
changes.  - Residual areas of lobular 
cancerization  - No definite residual DCIS  - 
Previous biopsy site changes.  - Margins free 
of involvement.  -Prognostic factors 
performed on previous biopsy    CS08-12007: 
ER +(97%), PR+(85%) ,PREOPERATIVE 
DIAGNOSIS:  Ductal carcinoma in situ, right 
breast, status post core biopsy, intermediate 
grade, cribriform type ER-PR positive. 
POSTOPERATIVE DIAGNOSIS:  Ductal 
carcinoma in situ, right breast, status post 
core biopsy, intermediate grade, cribriform 
type ER-PR positive. PROCEDURE:  Right 
mastectomy with level I axillary node 
excision. ,1.  This is a 00-year-old woman, who 
has had right mastectomy for recently 
diagnosed ductal carcinoma in situ of the right 
breast that also has features of lobular 
cancerization.  She is stage pT1N0M0 and I 
recommend hormonal therapy with 
tamoxifen 20 mg daily for 5  
       Inclusion Criteria:            1. Pathologically 
confirmed ductal carcinoma in situ of the breast 
or early invasive              breast cancer defined as 
pathologic stage Tis, T1, or T2, N0, N1mic, or N1a              
(pathologic staging of the axilla is required for all 
patients with invasive disease              but is not 
required for patients with DCIS only).            2. 
Treatment with breast conserving surgery.            
3. Final surgical margins must be negative, 
defined as no evidence for ductal carcinoma              
in situ or invasive breast cancer touching the 
inked surgical margin. If the invasive              or in 
situ breast cancer approaches within less than 1 
mm of the final surgical              margin, then a 
reexcision is strongly encouraged. Lobular 
carcinoma in situ at the              final surgical 
margin will be disregarded.            4. Age 40 years 
or older. This age cutoff is justified because 
breast cancers in women              under the age of 
40 are known to have a significantly higher risk of 
IBTR presumably              due to underlying 
biologic differences.            5. Female sex.            6. 
Attending radiation oncologist declares intention 
to treat the whole breast only and              that a 
third radiation field to treat regional lymph nodes 
is not planned (radiation              of the 
undissected level I/II axilla with high tangents is 
allowed).            7. If the patient has a history of a 
prior non-breast cancer, all treatment for this              
cancer must have been completed prior to study 
registration and the patient must have              no 
evidence of disease for this prior non-breast 
ductal 
carcinoma in 
situ 
right breast 
T1 
level I/II axilla 
DCIS 
ductal 
carcinoma 
Duct_adeno
carcinoma  
Duct_carcin
oma  
Duct_cell_ca
rcinoma 
Axillary_foss
a  
Axilla_struct
ure  
Axilla 
Armpit  
Structure_of
_axillary_fos
sa  
Axillary_regi
on Axillary  
Axillary_regi
on_structur
e 
Very Good  
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cancer.            8. Patients must be enrolled on the 
trial within 12 weeks of the later of two dates: 
the              final breast conserving surgical 
procedure or administration of the last cycle of              
cytotoxic chemotherapy.          Exclusion Criteria:            
1. Pathologic or clinical evidence for a stage T3 or 
T4 breast cancer.            2. Pathologic evidence for 
involvement of 4 or more axillary lymph nodes, 
or imaging              evidence of involvement of 
infraclavicular, supraclavicular, or internal 
mammary              lymph nodes.            3. Clinical 
or pathologic evidence for distant metastases.            
4. Any prior diagnosis of invasive or ductal 
carcinoma in situ breast cancer in either              
breast.            5. Current diagnosis of bilateral 
breast cancer.            6. History of therapeutic 
irradiation to the breast, lower neck, 
mediastinum or other              area in which there 
could potentially be overlap with the affected 
breast.            7. Patients not fluent in English or 
Spanish. (The Informed Consent will be available 
in              these two languages)            8. Patient is 
pregnant. 
2000024 
Subtle nodularity in the central subareolar 
region of the left breastSubtle nodularity in 
the central subareolar region of the left breast 
is identified as mildly prominent ductal 
elements. There is no suspicious finding 
within the left breast.  2. Post lumpectomy 
change on the right with an interval change in 
the mammographic appearance of the right 
breast with an 8 mm poorly defined zone of 
nodularity seen in the 12 o'clock position 
within the right breast with accompanying 
calcifications. Treated with lumpectomy 
followed by  radiotherapy. Ultrasound only 
questionably demonstrates a subtle zone of 
altered echotexture in this region. A discrete 
palpable lump is not identified on physical 
Inclusion Criteria:            1. Women with a 
histological diagnosis of breast cancer 
experiencing edema in the              ipsilateral arm 
such that there is a minimum 10% and  maximum 
40% increase in arm              volume over the 
unaffected arm (mild to moderate lymphedema).            
2. Patients must have completed all primary and 
adjuvant treatments (surgery,              
chemotherapy, radiotherapy) prior to 
randomization.            3. Patients must have their 
own fitted compression garment for daytime 
maintenance.            4. No past or current use of a 
night-time compression system for maintenance.  
Those              patients who have trialed a night-
time compression system in the past year must              
observe a six-month washout period before 
radotherapy 
edema in the 
ipsilateral 
arm 
Radiation_t
herapy  
Plesiotherap
y_radiation  
Therapeutic
_radiology  
Radiation_o
ncology 
Oedema 
Dropsy 
Hydrops 
Edematous 
Interstitial_e
dema 
Interstitial_o
edema 
Average 
patient has 
History of 
rather than 
experienci
ng edema - 
Questionab
le imaging 
findings  
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examination. History of edema in the 
ipsilateral arm SCREENING TO DIAGNOSTIC 
MAMMOGRAPHY AND BILATERAL BREAST 
ULTRASOUND: The patient presented for 
screening mammography. The breasts were 
imaged in the craniocaudal and MLO 
projections. Review of these images 
demonstrated an interval change with the 
appearance of a subtle zone of asymmetric 
density within the 12 o'clock position within 
the right breast with current.   
entering the trial.          Exclusion Criteria:            1. 
Clinical or radiological evidence of active disease, 
either local or metastatic.            2. History of 
contralateral breast cancer and axillary surgery.            
3. Serious non-malignant disease, such as renal 
or cardiac failure, which would preclude              
daily treatment and follow-up.            4. Patients 
for whom compression is contraindicated.            
5. Psychiatric or addictive disorders which 
preclude obtaining informed consent or              
adherence to the protocol.            6. Unable to 
comply with the protocol, measurement and 
follow-up schedule. 
Oedematou
s 
Edema_-
_lesion 
Oedema_-
_lesion 
Edema_-
_symptom 
Oedema_-
_symptom 
2000001 
Radical mastectomy :  - Breast tissue with 
proliferative fibrocystic changes.  - Residual 
areas of lobular cancerization  - Positive 
axillary lymph nodes.  - Margins free of 
involvement.  -Prognostic factors performed 
on previous biopsy    CS08-12007: ER(-) / 
PR(-), PREOPERATIVE DIAGNOSIS:  Ductal 
carcinoma in situ, right breast, status post 
core biopsy, intermediate grade, cribriform 
type ER-PR positive. POSTOPERATIVE 
DIAGNOSIS:  Ductal carcinoma in situ, right 
breast, status post core biopsy, intermediate 
grade, cribriform type ER-PR positive. 
PROCEDURE:  Right mastectomy.  This is a 00-
year-old woman, who has had right 
mastectomy for recently diagnosed ductal 
carcinoma in situ of the right breast that also 
has features of lobular cancerization. 
Inclusion Criteria:            1. Patient must accept 
the modified radical mastectomy            2. 
Patients with histologically confirmed ER(-) PR(-) 
and HER-2(-)            3. Positive axillary lymph 
nodes;negative axillary lymph node with age＜ 
35 years or Ⅲ              grade or intravascular 
cancer embolus.            4. Age between 18 years 
to 65 years            5. Able to give informed 
consent            6. Patients with an Eastern 
Cooperative Oncology Group (ECOG) 
performance score of 0 or              1.            7. Not 
pregnant, and on appropriate birth control if of 
child-bearing potential.            8. Adequate bone 
marrow reserve with ANC > 1000 and platelets > 
100,000.            9. Adequate renal function with 
serum creatinine < 2.0.           10. Adequate 
hepatic reserve with serum bilirubin < 2.0, 
AST/ALT < 2X the upper limit of              normal, 
and alkaline phosphatase < 5X the upper limit of 
normal. Serum bilirubin >              2.0 is 
acceptable in the setting of known Gilbert's 
syndrome.           11. No active major medical or 
psychosocial problems that could be complicated 
by study              participation.          Exclusion 
Criteria:            1. received neo-adjuvant therapy            
Radical 
mastectomy 
Positive 
axillary lymph 
nodes 
ER(-) 
PR(-) 
Mammecto
my  
Excision_of_
breast_tissu
e 
Axillary_foss
a  
Axilla_struct
ure  
Axilla 
Armpit  
Structure_of
_axillary_fos
sa  
Axillary_regi
on Axillary  
Axillary_regi
on_structur
e 
Structure_of
_lymph_nod
e  
Lymph_nod
e_structure 
Lymph_nod
e 
Average 
There is 
concept 
match on 
mastectom
y, ER, PR, 
and 
positive 
LN, 
however 
the patient 
had 
mastectom
y already 
and CT 
requires 
that 
patient 
accepts 
mastectom
y. Missing 
performan
ce status 
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2. Cardiac dysfunction documented by an 
ejection fraction less than the lower limit of              
the facility normal by multi-gated acquisition 
(MUGA) scan, or 45% by echocardiogram.              
-The rate of Disease recurrence            3. 
Uncontrolled medical problems.            4. 
Evidence of active acute or chronic infection.            
5. Pregnant or breast feeding.            6. Hepatic, 
renal, or bone marrow dysfunction as detailed 
above. 
Lymph_glan
d  
Lymphatic_g
land 
2000002 
Follow-up with surgical consultation:  
Postoperative changes and postradiation 
changes left breast. No ,Invasive, moderately 
differentiated, ductal carcinoma, mBR Grade II 
Negative for  lymphovascular space invasion. - 
Microcalcification within tumor. ,Infiltrating 
lobular carcinoma, mBR Grade I, 1 cm, in a 
random section from the lower outer 
quadrant (prognostic factors pending), 
located approximately 2 cm from the recent 
biopsy site. 2.Microscopic focus of residual 
infiltrating duct carcinoma, mBR Grade II, 0.1 
cm, adjacent to biopsy cavity (previous 
stereotactic biopsy, CS-08-10468, showed 0.8 
cm tumor). Right axillary lymph nodes 
metastasis. - Prognostic factors performed on 
previous biopsy ER 100%, PR 92%, Her-2/neu 
2+ (not amplified by SISH).  3.Biopsy-related 
changes with patchy adjacent atypical duct 
hyperplasia and fibrocystic change with 
associated microcalcifications. 4. One benign 
intramammary lymph node. 5. Skin and nipple 
negative for malignancy. 6. Margins of 
resection negative for atypia and ma 
Inclusion Criteria:            1. The participant has 
histopathologically-confirmed primary breast 
cancer in Japanese.            2. The participant is 
aged 20 years or older when informed consent is 
obtained            3. The participant has estrogen 
receptor (ER)-positive tumor cells and/or 
progesterone              receptor (PgR)-positive 
primary tumor. And HER-2 is negative.            4. 
The participant has breast cancer in the clinical 
stages of T1-T3, N-any and M0 by              TNM 
classification (the seventh edition, proposed by 
UICC in 2009). (No distant              metastasis to 
lung, liver and bone should be confirmed on the 
image-based diagnosis              at study 
enrollment. The image taken within 12 weeks 
prior to study enrollment is              also available 
for the diagnosis.) The number of axillary lymph 
node metastasis is              not limited.            5. 
Any operative procedure for breast cancer is 
acceptable. In principle, after              breast-
conserving surgery, the participant will receive 
postoperative radiation to              the conserving 
breast.            6. Neoadjuvant chemotherapy and 
adjuvant chemotherapy prior to study enrollment 
are              acceptable. (It is advisable the same 
kind of chemotherapy is performed at each              
site.)            7. The participant has a history of 
regular menstrual periods within 12 weeks prior 
to              study enrollment, or the participant has 
ER 
PR 
HER-2 
axillary lymph 
nodes 
metastasis 
operative 
procedure 
Axillary_foss
a  
Axilla_struct
ure  
Axilla 
Armpit  
Structure_of
_axillary_fos
sa  
Axillary_regi
on Axillary  
Axillary_regi
on_structur
e 
Structure_of
_lymph_nod
e  
Lymph_nod
e_structure 
Lymph_nod
e 
Lymph_glan
d  
Lymphatic_g
land 
Operative_p
rocedure 
Surgery 
Surgical 
Average 
Match on 
Confirmed 
diagnosis 
and ER, PR, 
Her status, 
and ax LNs. 
However, 
we are 
missing 
data on 
menopaus
al status 
and 
performan
ce status. 
Patient has 
post 
radiation 
changes 
suggesting 
that she 
received 
RT. 
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FSH of less than 40 mIU/mL and E2 of 10              
pg/mL or more measured within 12 weeks prior 
to study enrollment.  The participant              has 
not had a chemical menopause (i.e., FSH of less 
than 40 mIU/mL and E2 of 10 pg/mL              or 
more) within 12 weeks after completing adjuvant 
chemotherapy.            8. The participant is in a 
condition to receive study drug and Tamoxifen 
(TAM) within 12              weeks after surgery or 
after adjuvant chemotherapy prior to study 
enrollment.              Adjuvant chemotherapy prior 
to study is required to have been completed at 
the time              of study enrollment.            9. The 
participant has ECOG performance status of 
grades 0 or 1 at the time of study              
enrollment.           10. The participant meets the 
following criteria of hepatic, renal and bone 
marrow              functions on the laboratory test 
results at screening:                 -  Hepatic function: 
AST (GOT) ≤ 3.0 times the upper limit of normal 
(ULN) ALT                   (GPT) ≤ 3.0 times the ULN                 
-  Renal function: serum creatinine level < 1.5 
times the ULN                 -  Bone marrow function : 
white blood cell count ≥ 3,000/mm3 platelet 
count ≥                   100,000/μL hemoglobin ≥ 
10.0g/dL           11. The participant agrees to use a 
non-hormonal method of contraception through 
the              study period.          Exclusion Criteria:            
1. The participant has received neoadjuvant or 
adjuvant hormonal therapy for the latest              
breast cancer surgery.            2. The participant 
has received bilateral oophorectomy and 
bilateral ovarian              irradiation.            3. The 
participant has inflammatory breast cancer or 
bilateral breast cancer.            4. The participant 
has non-invasive ductal carcinoma.            5. The 
participant has multiple primary cancers, or a 
history of carcinoma in other              organs.            
6. The participant is pregnant or breast-feeding.            
Operation 
Surgical_pro
cedure 
Operative_p
rocedures 
Operations_
by_method 
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7. The participant has a history of hypersensitivity 
to synthetic LH-RH, LH-RH              derivative, 
TAM, TAM analogue (antiestrogen) or any 
component of the study drug.            8. The 
participant has a history of, or has been 
diagnosed with thromboembolism              
including myocardial infarction, cerebral 
infarction, venous thrombosis, and              
pulmonary embolism, or cardiac failure.            9. 
Patients whose QTcF interval exceeded 460 msec 
on the 12-lead electrocardiogram at              
screening. 
2000134 
 ,Document Type: Surg Path Final Report 
Document Date: 2010 Document Status: Auth 
(Verified) Performed by/Author: XXXX RT on 
2010  Verified By: XXXX MD on 2010 
Encounter info: 0000000000,, COL, 
Outpatient, 2010 - 2010  * Final Report *  
Specimen: (Verified) A U/S core bx left breast 
14g B U/S core bx left breast 14g C U/S SUROS 
left breast  Clinical Information: (Verified) A) 
U/S core biopsy left breast, 14g, location ? 
1:30 lateral.  Size 0.8 cm.  Left breast mass.  
Rad diff dx:  Favor invasive CA.   B) U/S core 
biopsy left breast, 14g, location ? 1:30 medial.  
Size 1.1 cm.  Left breast mass.  Rad diff dx:  
Invasive CA strongly favored.  C) U/S SUROS 
left breast, 9g vacuum assisted.  Location ? 
3:00, size 6 mm. Note is made that the patient 
has undergone a prior right-sided 
lumpectomy. in 1999 Left breast mass.  Rad 
diff dx:  Favor invasive CA vs FCC with fibrosis. 
Post radiation changes left breast  Invasive 
ductal carcinoma in situ with lobular features.  
Gross Description: (Verified) Specimen A:  
Specimen received fresh and placed in 
formalin (on 2010 
DISEASE CHARACTERISTICS:            -  Female 
patients newly diagnosed with breast carcinoma 
including ductal carcinoma in              situ (DCIS)                 
-  Stage 0-IIIA disease            -  Status post-
lumpectomy, -quadrantectomy, or -mastectomy            
-  Plan to receive adjuvant radiation to the whole 
breast or chest wall and/or regional              lymph 
nodes            -  No sites that cannot send 
blood/urine specimens to Wake Forest by 
overnight (next              day) express shipping          
PATIENT CHARACTERISTICS:            -  *This 
stratum is closed as of April 25, 2012.            -  No 
patients who do not understand English and are 
unable to complete form with              assistance          
PRIOR CONCURRENT THERAPY:            -  Total 
dose > 40 Gy, dose per fraction > 1.8 - 2.0 Gy, use 
of 2D, 3D-conformal, or              intensity-
modulated radiation therapy (IMRT) treatment 
techniques allowed; a daily              fraction of 2.7 
Gy to the whole breast is suggested for 
hypofractionated regimens            -  Concurrent 
and sequential boost techniques are allowed for 
both standard and              hypofractionated 
regimens            -  Adjuvant hormonal therapy will 
be allowed prior to, during, and/or after 
radiotherapy              (RT) at the discretion of a 
medical oncologist            -  Targeted therapies, 
lumpectomy 
radiation 
ductal 
carcinoma in 
situ 
Tylectomy 
Tylectomy_
of_breast 
Lumpectom
y_of_breast 
Breast_lump
ectomy 
Excision_of_
breast_lump 
Excision_of_
lesion_of_br
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Radiation_t
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Therapeutic
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Duct_adeno
carcinoma 
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oma 
Duct_cell_ca
rcinoma 
Average 
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(?invasive), 
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y, and 
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such as Herceptin, will be allowed prior to, 
during, and/or after              RT at the discretion of 
the medical oncologist            -  No prior radiation 
to the involved breast or chest wall            -  No 
concurrent chemotherapy            -  No patients 
who underwent breast reconstruction following 
mastectomy                 -  Placement of tissue 
expanders and implants are not allowed            -  
No patients who have undergone MammoSite® 
or any other form of brachytherapy as well              
as those who will be treated with skin-sparing 
IMRT            -  Patients may not be concurrently 
enrolled in a protocol that involves treatment of              
the skin, i.e., applying lotions/moisturizers                 
-  Protocols that do not involve treatment of the 
skin are allowed 
Ductal_carci
noma 
 
164 
 
 
CURRICULUM VITAE 
 
EUISUNG JUNG 
University of Wisconsin-Milwaukee 
 
EDUCATION 
August 2015  Ph.D in Information Technology Management  
Minor : Computer Science 
University of Wisconsin-Milwaukee 
Sheldon B. Lubar School of Business 
2002 Master of Business Administration (concentration in MIS) 
Kyungpook National University, Daegu, Korea. 
Title of Thesis : Relationship between Internet-based B2B system and BPI 
2000 Bachelor of Business Administration 
Kyungpook National University, Daegu, Korea. 
 
DISSERTATION TITLE 
Three Essays on Enhancing Clinical Trial Subject Recruitment Using Natural Language 
Processing and Text Mining 
 
JOURNAL PUBLICATIONS 
• Kwak, D.-H., Kizzier, D., Zo, H., and Jung, E. 2012. “Cross-Cultural Investigation of 
Security Knowledge Process,” International Journal of Business Information Systems 
(10:1), pp. 1-19. 
• Kwak, D.-H., Kizzier, D., Zo, H., and Jung, E. 2011. “Understanding Security Knowledge 
and National Culture: A Comparative Investigation between Korea and the U.S,” Asia 
Pacific Journal of Information Systems, (21:3), pp. 51-69. 
• Euisung Jung, Changkyo Suh, , "Effect of internet-based B2B system on BPI", Economics 
and Business Papers, 32(1), 101-119, The Institute of Economics and Business Research 
Kyungpook National University, 2004.08.23 
 
165 
 
 
TEACHING EXPERIENCE 
2014 - Present Assistant Professor 
College of Business and Innovation, The University of Toledo 
– BUAD3050 Information Technology Management 
– INFS3780 / 6930 Enterprise Resource Planning 
2014 Spring Adjunct Faculty 
Sheldon B. Lubar School of Business, University of Wisconsin-Milwaukee 
– BUS ADM 532 Web Development for Open Business Systems 
 
PROFESSIONAL ACTIVITIES 
Reviewer 
– Journal of Information Technology Theory and Application (JITTA) 2013 
– International Conference on Information Systems (ICIS), 2012, 2013, 2014 
– Americas Conference on Information Systems (AMCIS), 2010, 2011, 2012, 2013 
– Hawaii International Conferences on System Sciences (HICSS), 2011 
 
HONORS AND AWARDS  
 
• Sheldon B. Lubar Doctoral Scholarship, University of Wisconsin–Milwaukee (2013) 
• Business Advisory Council Doctoral Scholarship, University of Wisconsin – Milwaukee 
(2012) 
• Graduate Student Travel Award, University of Wisconsin – Milwaukee (2010, 2011, 2012, 
2013) 
• Innovative Research Award, National Research Council for Economics, Humanities and 
Social Sciences (2007) 
• Award for meritorious service, President of Korea Environment Institute, 2007 
• Outstanding Research Scholarship, Kyungpook National University (2000) 
• Winner of the semifinals, National University Armature Tennis Tournament (1998) 
• Exemplary soldier award, Commander of Republic of Korea Army 22 Division (1996) 
• Academic Excellent Scholarship, Kyungpook National University, (1993) 
 
